Download CANCER RESEARCH INSTITUTE ANNUAL REPORT 2003

CANCER RESEARCH INSTITUTE
ANNUAL REPORT 2003
PAST IS PROLOGUE
Contents
Senior Staff
1
THE CRI STORY
11
MESSAGE FROM THE CHAIRMAN
13
HOW TO SUPPORT THE WORK
16
MAJOR PROGRAMS
21
SPECIFIC PROJECTS
24
ESPECIALLY GENEROUS DONORS
37
THE CRI LEADERSHIP
42
FINANCIAL STATEMENTS
Jill O’Donnell-Tormey, Ph.D.
Executive Director
Lynne A. Harmer
Director of Special Events &
Grants Administration
Joseph A. Isahack
Network & Systems Manager
Alfred R. Massidas
Controller & General Manager
MaryLee Thorne
Director of Development
National Headquarters
681 Fifth Avenue
New York, NY 10022-4209
Tel. 212-688-7515
Fax 212-832-9376
Toll-free 1-800-99CANCER
E-mail [email protected]
www.cancerresearch.org
Volunteer Offices
12011 San Vicente Boulevard
Los Angeles, CA 90049
Tel. 310-471-2720
101 University Avenue, 4th Floor
Palo Alto, CA 94301
Tel. 650-365-6441
184 Fisher Avenue
Brookline, MA 02445
Tel. 617-566-0100
754 Walker Road, 2nd Floor
Great Falls, VA 22066
Tel. 703-759-0835
THE CANCER RESEARCH INSTITUTE STORY
CANCER RESEARCH INSTITUTE
1
“At the end of two weeks the neck tumor
had disappeared...”-Dr. William B. Coley
Dr. William B. Coley (1862-1936)
was a prominent New York City
surgeon from the 1890s until the
1930s. The success of his
pioneering vaccine against certain
types of cancer has earned him
recognition as “the father of
cancer immunotherapy.” His
great-grandson, Geoffrey O. Coley,
is a Trustee on the CRI Board.
Immunology is recognized today as the most promising area of cancer
research, and the Cancer Research Institute is leading the way.
If you had predicted this in 1953, when CRI was founded, you would have been
considered naive. Immunology was immature, and cancer immunology in particular
was regarded with doubt by the medical establishment.
The emergence of cancer immunology and CRI against great odds is a drama
that began over a century ago, when Dr. William Coley, a young New York City surgeon, observed an amazing fact: in cancer patients who summoned the resources
to fight off severe operating-room infections, tumors sometimes melted away.
Could the patients’ stiffened powers of resistance also be fighting off the cancer?
On May 3, 1891, Coley inaugurated the field of cancer immunology by injecting
a culture of heat-killed bacteria into a hopelessly ill patient named Zola, who had a
fist-sized neck tumor. Encouraged by an improvement in the man’s condition, Coley
tried different culture preparations until he got the reaction he hoped for.
“The tumor of the neck began to break down on the second day,” he wrote in
his diary. “At the end of two weeks the neck tumor had disappeared…”
Mr. Zola went on to live another 81⁄2 years. Coley refined his methods, creating a fluid known as “Coley’s toxins,” which produced many more apparent cures.
“I went through 15,000 letters and
papers...he’d never thrown away a
thing!”
-Helen Coley Nauts
CANCER RESEARCH INSTITUTE
3
You might think he would have been hailed as a Louis Pasteur.
Such was not the case.
The basic reason is that his successes were unpredictable and inexplicable,
since almost nothing was known about the immune system. This would remain true
for decades to come.
In addition, after “a few physicians, with indifferent preparations of the toxins,”
as Dr. Coley put it, “failed to obtain good results,” the approach was quickly dismissed by medical journals.
The dismissal was duly noted. Hospitals and the doctors who worked in them
were dedicated to surgery, soon to be joined by radiation, and eventually,
chemotherapy, to create a trinity of accepted practice. A friendly medical director
of the hospital where Coley worked once confided to him that doctors there were
allowed to “go out of their way, almost maliciously, to deprecate the toxins.”
Dr. Coley enjoyed a successful career as a surgeon, but “Coley’s toxins” were
marginalized, never to receive proper clinical testing (see p. 12)—and the appeal
of cancer immunology as a subject worthy of talented researchers was seriously
dimmed.
Helen Coley Nauts (1907-2001)
co-founded CRI with
Oliver R. Grace (1909-1992) to
advance the work begun by her
father, Dr. William Coley. She was
the first woman of science
since Dr. Marie Curie to win the
National Institute of Social
Sciences’ Gold Medal for
Distinguished Service to Humanity.
Imagine a well-bred young woman who attends Miss Porter’s School in
Connecticut, studies landscape design, marries a banker, then settles down to raise
children and do volunteer work. Could she possibly have a place in our story?
Yes, if her name is Helen Coley Nauts.
After the death of her father, Dr. William Coley, Helen Coley Nauts discovered
a daunting jumble of his records inside the family barn in 1938. “I went through
15,000 letters and papers in two years,” she later said. “He’d never thrown away
a thing!”
As she slowly brought the material into order, she realized that her father had
made a genuine medical breakthrough. The idea ignited her, and she resolved to
present it convincingly to the world.
Helen Nauts taught herself biology and oncology, tracked down patients who
had received “Coley’s toxins” to learn the long-term results, and sought out cancer
doctors who were familiar with the treatment. Someone once asked her why her
efforts were so untiring: “People are dying when I’m not working,” she replied.
Meetings with doctors and patients were getting sizable by the early 1950s.
The philanthropist Oliver Grace, a childhood friend, came forward with his wife,
Lorraine: Why not meet at their large East Side Manhattan apartment? “Helen
brought the doctors,” recalls Lorraine Grace, “and we supplied the spaghetti dinners.”
In 1953, armed with meticulous analyses of 1,000 “Coley’s toxins” cases and
the advice of open-minded oncologists, Helen Nauts and Oliver Grace co-founded
4
CANCER RESEARCH INSTITUTE
the Cancer Research Institute. Its mission: to promote the field pioneered by Dr.
Coley. Its initial budget: $15,000.
Over the next 20 years, CRI gained recognition as the clearinghouse for information on cancer immunology, conducting a worldwide correspondence. It published monographs of Helen Nauts’ data compilations, so precise that they are still
consulted by cancer researchers for clues about the disease. The Institute’s network of scientists and doctors grew, and with the help of a small circle of generous
friends like the Graces, Julian Robertson, Anna-Maria and Stephen Kellen, and
William Murray, it was able to support an increasing number of research projects.
The workings of the immune system, as complex as a grand symphony, were
slowly becoming better understood; cancer immunology made some advances, too.
For example, scientists found that when cancer was induced in laboratory mice, the
surface of the tumor cells bore characteristic bits of protein, called antigens, which
could immunize other mice against transplants of the tumors.
On the other hand, medical institutions (as well as their funding sources) still
put their faith mostly in surgery and chemotherapy. The reputation of cancer
immunology was not helped when, in 1965, “Coley’s toxins” were officially blacklist-
For the past half century, Lorraine
Grace has been a great friend of
CRI, co-founded by her late
husband, Oliver R. Grace; their
early support helped to quickly
establish the Institute as a
respected effort. She serves on
the CRI Board of Trustees along
with her son, Oliver R. Grace, Jr.
ed, together with apricot-pit extract and mistletoe, as a questionable treatment.
Julian Robertson, now a Vice Chairman of the CRI Board of Trustees, remembers those days well. ”How many good cancer-immunology teams were there in the
world then? Five or six at most.”
Fortunately, one of those teams included a farsighted researcher named Dr.
Lloyd Old.
In 1967, CRI awarded an initial grant to Dr. Old, who hoped to discover whether
antigenic reactions similar to those in mice also occurred in man. He had a larger
vision, too. Turning the promise of immunotherapy into life-saving reality would take
“Helen brought the doctors to our apartment
and we supplied the spaghetti dinners.”
- Mrs. Oliver(Lorraine) Grace
-Mrs. Oliver (Lorraine) Grace
CANCER RESEARCH INSTITUTE
5
“How many good cancer-immunology teams
were there? Five or six at most.” -Julian H. Robertson, Jr.
Philanthropist Julian H. Robertson,
Jr., shown above circa 1974,
joined the CRI Board in 1968; he
became President in 1974,
when Oliver Grace was named
the first Board Chairman, and is
currently a Vice Chairman. He is
Founder and Chairman of Tiger
Management, which grew into the
world’s largest hedge-fund group.
a broad, long-term effort. Much still had to be learned first about how the immune
system recognized and attacked foreign substances.
CRI’s medical advisors were impressed. While the Institute had begun with a
focus on Dr. Coley’s work, it had steadily moved deeper into immunology, and needed a first-rate immunologist to lead it. In 1971, Dr. Old was appointed CRI’s medical director.
He set out at once to expand CRI’s scope, bringing many of the world’s most
distinguished immunologists, including Nobel Prize winners, to the Institute’s
Scientific Advisory Council. It became a body that could speak with unimpeachable
authority.
He also persuaded the Board of Trustees to establish a new Postdoctoral
Fellowship Program that would attract outstanding young scientists to immunology.
Half the year’s budget was invested in the program—the first of several, which, to
date, have helped more than 2,750 immunologists at universities, research centers, and hospitals worldwide.
6
CANCER RESEARCH INSTITUTE
“The Nixon declaration of a ‘War on Cancer’
encouraged some unrealistic expectations.”
-Lloyd J. Old, M.D.
The 1970s and 1980s were exciting, turbulent times in cancer research. After
President Nixon signed the National Cancer Act, the disease became a hot topic in
the media; lucrative potential “cures” and “star” researchers made the covers of
newsmagazines, only to be virtually forgotten in a year. “The Nixon declaration of a
‘War on Cancer’ encouraged some unrealistic expectations,” says Dr. Old.
More than one observer has remarked on the almost manic-depressive way
that immunological substances like interferon and interleukin-2 were greeted with
enthusiasm, then prematurely discounted. As we now know, none of them is a
“magic bullet,” but careful investigation has shown them to be of value under certain circumstances, or in combination with other treatments.
The status of cancer immunology fluctuated with these ups and downs. Doubts
were reinforced when experiments in the late 1970s found no evidence to support
the widely accepted theory that the immune system constantly seeks out and
destroys emerging cancer cells, and that tumors develop when this immunosur-
Lloyd J. Old, M.D., shown above
circa 1971, is Director of the
CRI Scientific Advisory Council,
Director and CEO of the global
Ludwig Institute for Cancer
Research, and a longtime
researcher at Memorial SloanKettering Cancer Center. He and
his colleagues have been making
significant discoveries in tumor
immunology since the 1960s.
CANCER RESEARCH INSTITUTE
7
veillance fails. The theory has only recently been proved (see p. 23); an unsympathetic mind might have concluded that cancer immunology was fundamentally
flawed.
CRI Vice Chairman Carter Bales recalls those competitive days. “It was obvious,” he says, “that we had to reach out for a broader base of support.”
While retaining the faithful core of supporters from its early years, CRI began
a sustained communications program to inform the public and win additional funding; 30,000 new donors were gained between 1978 and 1982 alone. People saw
As CRI President (1981-1984),
Carter F. Bales, shown below
circa 1981, worked closely with
Chairman Oliver Grace to create
a successful public-outreach
effort. He is now a CRI Vice
Chairman and Co-Managing
Partner of the Wicks Group of
Companies, L.L.C., a mediafocused private-equity firm.
that CRI was championing a vital cause, virtually neglected by others. They appreciated the fact that, then as now, an uncommonly high percentage of the money
they gave actually went to research.
Competition for research talent was intensifying, too, at the same time as
promising areas for investigation in immunology were opening up at an even faster
rate. In 1986, CRI established the Investigator Award Program as a complement
to its Postdoctoral Fellowships.
“It was obvious we had to reach out for a
broader base of support.” -Carter F. Bales
8
CANCER RESEARCH INSTITUTE
The new program was designed to support accomplished assistant professors
undertaking their first independent investigations in basic and tumor immunology—
a challenging period that can determine the course of a career for years to come.
“Immunology research needed a booster shot,” says Jacques Nordeman, who was
CRI’s President at the time. “The Investigator Award delivered it.”
CRI’s decades of investment in immunology paid significant dividends in the
1990s. Armed with deeper knowledge of the immune system’s basic workings, scientists were able to create techniques for identifying cancer antigens suitable for
testing in vaccines. They learned how to construct many types of vaccines to deliver a given antigen, and developed methods to precisely monitor the results.
As Dr. Lloyd Old had envisioned, the efforts now represented a broad, long-term
commitment by immunologists from the USA, England, Germany, and France to
Jacques C. Nordeman
(CRI President, 1986-1991)
helped develop the Investigator
Award Program to invigorate
the field of immunology. He is
currently a Vice Chairman of
the CRI Board of Trustees and
Chairman of Nordeman Grimm,
a leading executive-search firm.
“Immunology research needed a booster
shot; the Investigator Award delivered it.”
-Jacques C. Nordeman
CANCER RESEARCH INSTITUTE
9
“Cancer immunologists from around the
world were finally on the same page.”
-Donald J. Gogel
Vice Chairman Donald J. Gogel
became CRI President in 1991;
after the death of Oliver Grace in
1992, he was appointed
Chairman and served until 1997.
He is President and CEO of
Clayton, Dubilier & Rice, a
long-established and respected
private-equity investment firm.
Russia and the People’s Republic of China…but one factor was missing.
Coordination.
With that need in mind, CRI initiated its International Symposia Series in 1994.
These annual meetings convene researchers from dozens of countries and bring
them up to the minute on progress in the field. “Cancer immunologists from around
the world were finally on the same page,” notes CRI Vice Chairman Donald Gogel.
The need for coordinating research efforts was even more critical. Research
often consists of stand-alone projects that follow their own guidelines. Results are
hard to compare and learn from. Proprietary interests get in the way of sharing
those results.
Thanks to the stature of the Scientific Advisory Council, CRI has been able to
introduce a collaborative research model that brings together the best
researchers from different institutions and focuses them on the most promising
topics, using standardized methods and freely discussing their findings.
Beginning in 1999, the model was first employed in what is now called the
Cancer Antigen Discovery Collaborative, dedicated to identifying antigens in colon,
breast, and prostate cancer. “The search for cancer cells’ weak points was speeded up through a team approach,” reports Vice Chairman Carlos Ferrer.
10
CANCER RESEARCH INSTITUTE
“The search for cancer cells’ weak points
was speeded up through the team approach.”
-Carlos A. Ferrer
As CRI entered the new millennium, the proven model was applied to tests of
vaccines on actual patients, through our Cancer Vaccine Collaborative. Developed
jointly with the Ludwig Institute for Cancer Research, the CVC unites a growing
number of researchers in a worldwide quest that should ultimately uncover the
basics of effective cancer immunization.
Virtually every major research institution in the world now has scientists on
staff who have been or are being funded by CRI, with fresh talent on the way. The
journey begun by Dr. Coley isn’t over, but effective treatments appear to exist—a
new vaccine to prevent cervical cancer, for example (see p. 32). Researchers are
confident that in the foreseeable future, doctors will have a wide range of
immunotherapies to save lives and reduce the need for drastic remedies.
With your help, that day will be here sooner rather than later.
During his Chairmanship of CRI
(1997-2001), Carlos A. Ferrer
was keenly involved in rolling out
the Institute’s new collaborative
research model. He is a Partner
and Co-Founder of Ferrer
Freeman & Company, a leading
healthcare-focused privateequity firm.
A MESSAGE FROM THE CHAIRMAN OF THE BOARD OF TRUSTEES
CANCER RESEARCH INSTITUTE
11
“Our need for contributions here is
what doctors call time-critical.”
-Ann W. Jackson
Ann W. Jackson, Group President
of Time Inc. Women’s Group, has
been Chairman of the CRI Board
of Trustees since 2001;
previously, she was a Trustee.
Her commitment to CRI
CRI’s budget has grown from $15,000 in 1953 to $15 million in fiscal 2003,
a thousand fold increase.
I can assure our donors that their money is well spent.
Chemotherapy, radiation, and surgery are reaching their limits of efficacy.
heightened dramatically when she
Thanks largely to CRI, cancer immunology is moving rapidly out of the lab into the
was diagnosed with breast cancer
clinic, promising a new level of successful therapies…and CRI is the only organi-
(prognosis excellent) in 1999.
zation devoted to cancer immunology.
Our need for contributions here is what doctors call time-critical. Donations are
not salted away in a war chest, but go directly to underwrite current work that
touches the lives of cancer patients today as well as in the future.
Clinical trials of new vaccines on patients increased this past year as the CRIfunded Cancer Vaccine Collaborative expanded beyond New York City. This innovative team approach, developed by CRI and the Ludwig Institute for Cancer
12
CANCER RESEARCH INSTITUTE
Research, now also involves the Mayo Clinic in Minnesota and institutions in
Japan, Switzerland, Germany, and the U.K. in a powerful, united effort.
Meanwhile, our Cancer Antigen Discovery Collaborative has isolated promising
new antigens for the CVC to test in vaccines in the coming year.
And our long-established commitment to nurturing talented immunologists was
stronger than ever in 2003; we provided support for 248 grants at 98 institutions in nearly half the states and more than a dozen countries.
I want to thank the especially generous donors who made this possible. Notably,
The Atlantic Philanthropies continued its four-year, $20-million grant, which we
leveraged to raise more gifts of $500,000-plus than ever before. Gratitude is
also due to the CRI Board of Trustees. Board members made our fundraising
events rousing successes—the Annual Awards Dinner netted a record
$705,000—and their personal giving is at an all-time high.
I want to welcome Heidi Ueberroth, Executive Vice-President of NBA
Entertainment, and Frank V. Sica, Managing Partner of Soros Private Funds
Management, who join CRI as new Board members, and say thanks to resigning
members Richard S. Braddock, Chuck Scarborough, and Howard P. Berkowitz for
years of service. We’re fortunate Howard will continue as an honorary Trustee
and champion our Gar Reichman Fund.
Past, they say, is prologue. This next year should be the most exciting yet for
CRI and cancer immunology. Our fundraising goals have risen commensurately.
We must further expand the CVC and CADC to keep up the momentum of discovery, without sacrificing our assistance to upcoming immunologists who will
carry it into the future. One project of special interest: a possible test of “Coley’s
toxins” (after a century of neglect) in a standardized manner, as an adjuvant or
general immune-system booster in CVC trials.
When Helen Nauts used to ask Dr. Lloyd Old why it took so long to do anything,
he always replied: “Helen, it’s taken this many years for the science to catch up
to your father’s vision.”
I hope you’ll take a moment to look over the following pages and see how you
can help complete the task.
HOW TO SUPPORT THE WORK
CANCER RESEARCH INSTITUTE
13
“The aim is to extract the maximum
discovery from every dollar we receive.”
-Jill O’Donnell-Tormey, Ph.D.
Jill O’Donnell-Tormey holds
a Ph.D. in cell biology and was a
CRI Fellow at Rockefeller University
before joining the Institute as
Director of Public Information in
1987. She has served as Executive
Director of CRI since 1993.
Many Nobel Prize winners and members of the National Academy of Sciences
believe that life-saving immunotherapies will be on hand for individual types of cancer within 10 to 15 years.
There’s no better way to contribute to this end than by giving to CRI. The
Institute is the acknowledged charitable leader in cancer immunology. Our Scientific
Advisory Council actively shapes its course. And you can feel confident that your
donation, in any amount, in any of the ways outlined below, will do the most good
possible.
In the most recent rating of charities by the American Institute of Philanthropy,
called “the nation’s preeminent charities watchdog,” CRI was one of only two cancer organizations to receive an A+ for fiscal disclosure and integrity. This reinforces
a reputation for financial commitment (recognized by Forbes magazine and many
others) that goes back decades.
During 2003, only 10 cents of every dollar we received went for the mechanics of fundraising and administration—a sense of priorities and efficiency of operation seldom matched by other cancer charities.
As always, your gift is deductible for federal and state tax purposes as provided by law; CRI is tax-exempt under section 501(c)(3) of the IRS code.
14
CANCER RESEARCH INSTITUTE
Outright Gifts
Cash: Donations payable by check, money order, or credit card to the Cancer
Research Institute immediately assist researchers all over the world; CRI’s Web
site is equipped with a secure server for on-line contributions. Such gifts entitle you
to the most generous charitable deduction. And donors who give $100 or more
receive a year’s subscription to The Researcher, with news of CRI activities and
developments in cancer immunotherapy.
Property other than cash: Securities, real estate, automobiles, collectibles, and
similar properties are a tax-efficient way to make meaningful gifts with little or no
effect on current income.
Workplace giving programs: Your company may have a payroll deduction plan
through which you can contribute to CRI; ask your human resources department.
CRI participates in the Combined Federal Campaign (member #0517), state and
local government employee campaigns, and in corporate workplace giving as a
member of the Community Health Charities Federation throughout the United
States. We also participate in United Way Donor Choice programs.
Matching gift programs: Many companies double or triple charitable donations
made by their employees. Contact your human resources department to find out if
your employer matches contributions.
Planned Gifts
The Cancer Research Institute is a living monument to its founder, Helen Coley
Nauts. Appropriately, we have created the Helen Coley Nauts Society to acknowledge those who carry on her legacy by including CRI in their financial and estate
plans. The most common gift of this kind is a bequest made through a living trust
or inclusion of CRI in your will as a beneficiary of cash, securities, real estate, or
personal property. Your bequest should include CRI’s federal tax ID number (131837-442) and a statement such as the following:
“I bequeath to the Cancer Research Institute, Inc., a not-for-profit corporation
of the State of New York, having its principal office at 681 Fifth Avenue, New York,
New York 10022, the sum of $ _____ for its general corporate purposes.”
Bequests can take a variety of forms, including specific dollar amount bequests,
residuary bequests, and contingent bequests.
CANCER RESEARCH INSTITUTE
15
The Helen Coley Nauts Society also includes those who name the Institute as a
beneficiary of their life-insurance policy, retirement plan, or lead trust; who make a
life income gift through a charitable gift annuity or charitable remainder trust; or
who establish an endowment. Many of these “planned gifts” can offer donors tax
advantages and income benefits while allowing them to do more for CRI. You
should, of course, always consult your attorney and tax adviser for the formal writing of your will and to discuss the tax implications of any form of planned giving.
Special-Purpose Giving
Memorials and special occasions: You can make an outright or planned gift in
memory of a relative, friend, or colleague, and CRI will send an announcement of
the gift to whomever you specify. A donation of this sort can also serve as a tribute in recognition of a birthday, anniversary, or other milestone.
Designated support: Although contributions for general purposes are especially
welcome, you may wish to support a specific area of our work. Gifts can be designated for any of CRI’s programs, which are listed beginning on p. 16, or for regional research funds.
You may prefer to designate a fellow or investigator for support. Postdoctoral
Fellowships and Investigator Awards can be named in memory or in honor of a
loved one. An annual donation of $45,000 over a three-year period supports a fellow; a four-year annual commitment of $50,000 per year supports an investigator,
and $75,000 per year for three years supports investigators participating in the
Cancer Vaccine Collaborative. Benefactors receive yearly research progress
reports and are acknowledged in papers published about the work they have supported.
To help you, your company, or your client make the most fitting and fulfilling
contribution to CRI, please call MaryLee Thorne, our Director of Development,
at 1-800-99CANCER or e-mail her at mar [email protected].
“Building the field of cancer
immunology meant thinking at least
a decade ahead.”
-Lloyd J. Old, M.D.
MAJOR PROGRAMS
CANCER RESEARCH INSTITUTE
17
More than 30 years ago, CRI introduced its Postdoctoral Fellowship Program
at the urging of Dr. Lloyd J. Old, to answer the long-term need for researchers who
would build the future of cancer immunology.
We now provide funding at every level of inquiry, from coordinated clinical trials
to the most basic research, and support scientists at all career levels.
In addition to highly competitive research grants awarded selectively by our
Scientific Advisory Council, we sponsor a seminal international symposium on cancer immunology each year; educate the public about immunology and immunotherapy; and present awards to scientists and laypersons who have made outstanding
contributions to the field.
The following programs form the core of CRI’s commitments.
RESEARCH PROGRAMS
Predoctoral Emphasis Pathway in Tumor Immunology: The Predoctoral Emphasis
Pathway was initiated in 1998 in order to capture the interest of talented
researchers at the earliest stage. Through this program universities may apply for
training grants that support doctoral students planning to pursue a career in cancer immunology. A seven-person panel including Scientific Advisory Council members and outside reviewers selects recipients of this grant, which provides
$450,000 over a four-year period. CRI awarded two grants in fiscal 2003.
Postdoctoral Fellowship Program: In 1971, the Postdoctoral Fellowship Program
was established to support and train young immunologists at leading universities
and research centers around the world.
A panel of 14 scientists drawn from our Scientific Advisory Council rigorously
evaluates each candidate, the intended sponsor and training environment, and the
nature and feasibility of the proposed project.
At a 2001 ceremony honoring
Lloyd J. Old for 30 years of
service as Director of the
Scientific Advisory Council,
Chairman Carlos Ferrer cited
Dr. Old’s provident efforts to
bring talented scientists into
immunology as a key reason
why he is “the true lifeblood and
visionary for this organization.”
Fellowship appointments are for three years. The stipend for new fellows is
$40,000 for the first year, $42,000 for the second, and $44,000 for the third.
A yearly allowance of $1,500 is provided to the host institution to help meet
expenses for research supplies, travel to scientific meetings, and health insurance
incurred on behalf of the fellow. In fiscal 2003, CRI awarded 33 fellowships for a
total of $4.22 million.
Investigator Award Program: The Investigator Award Program, established in
1986 to complement our Postdoctoral Fellowships, has supported 87 accomplished assistant professors undertaking their first independent investigations in
basic and tumor immunology. By awarding these researchers $50,000 a year for
a period of four years, the program provides flexibility and a degree of stability during this very challenging period.
18
CANCER RESEARCH INSTITUTE
A seven-person panel including Scientific Advisory Council members and outside
reviewers selects recipients of this prestigious award based on the applicant’s
entire body of research rather than on a single project. In fiscal 2003, CRI awarded $1 million to support five new investigators.
Clinical Investigation Program: The Clinical Investigation Program is composed of
three distinct initiatives.
Cancer Vaccine Collaborative: Created in partnership with the Ludwig Institute for
Cancer Research, the CVC is an innovative network of coordinated early-phase cancer vaccine trials at hospitals and medical centers around the world. These multiple, yet parallel trials, which use defined antigens, standardized treatment protocols, uniform monitoring methodologies, and centralized data collection, are providing comparable results that will teach us how to effectively immunize against cancer. In fiscal year 2003, grants totaling $2.2 million were awarded to investigators
at the participating CVC sites.
Cancer Antigen Discovery Collaborative: Mobilizes invited experts to work cooperatively on defined tasks toward a common goal of identifying the targets on cancer cells that can serve as the basis for vaccines and antibody therapies.
Seventeen grants totaling $800,000 were awarded in fiscal 2003.
Grants Program: Supports individual preclinical and clinical research in three specific areas: cancer antigen identification for vaccine and antibody therapies; characterization of the immune response to cancer antigens; and the fashioning of vaccine and antibody-based therapies for cancer. CRI awarded $1.27 million in fiscal
2003 to support five preclinical studies.
Designated Grants Program: Under its Designated Grants Program, the Institute
supports research projects for which, in most cases, funds have been specifically
raised. Among the special categories through which designated grants are awarded are the following longstanding programs:
AIDS Program: CRI provides funding to scientists investigating how the AIDS virus
infects the cells of the immune system and how the virus can be deterred. Our
commitment to AIDS research dates back to 1983 when we were among the first
private research funding organizations to recognize the urgency of the emerging
AIDS epidemic and to see the relationship of the disease to certain types of cancer. Current AIDS-related projects are supported through our established research
programs.
Concern Foundation Program: Since 1981, CRI and the Concern Foundation for
Cancer Research of Beverly Hills, CA, have provided joint support to the laboratory of Dr. George Klein at the Karolinska Institute in Stockholm, Sweden. Dr. Klein is
CANCER RESEARCH INSTITUTE
19
one of the world’s leading tumor biologists, having pioneered research into the role
of the Epstein-Barr virus in causing Burkitt’s lymphoma (a type of cancer) and other
diseases. Moreover, Dr. Klein’s laboratory has been a training center for a large
number of outstanding scientists from Russia and other former Communist countries.
Gar Reichman Program: Through the Gar Reichman Fund, CRI supports the work
of Dr. Malcolm A.S. Moore, who heads the Gar Reichman Laboratory and holds the
Enid A. Haupt Chair in Cell Biology at Memorial Sloan-Kettering Cancer Center in
New York City. The Gar Reichman Foundation was established in 1971, in memory of Gar Reichman, to fund research on leukemia and other blood-related diseases. The foundation entrusted its funds to CRI in 1988.
EDUCATIONAL PROGRAMS
International Symposia Series: CRI’s International Symposia Series is a powerful
means of shaping the future course of cancer research. CRI developed these annual meetings to focus attention on progress in cancer vaccines and antibody-based
therapies, the two central approaches of cancer immunology. The tenth meeting in
the series took place in fiscal 2003 and celebrated the launch of the Cancer
Research Institute/Ludwig Institute for Cancer Research Cancer Vaccine
Collaborative and highlighted the major advances in the field of tumor immunology
that have laid the scientific foundation for this auspicious program. Specifically, the
meeting focused on four topics (1) Cancer Immunosurveillance/Immunoediting; (2)
Cancer Antigen Discovery; (3) Monitoring the Immunological Response to Human
Cancer; and (4) Cancer Vaccine Development. More than 350 scientists and clinicians from around the world attended the three-day meeting.
Public Information Program: As part of its Public Information Program, CRI
answers public inquiries about the field of cancer immunology and helps locate clinical trials of immunotherapies through a medical database, the Physician Data
Query (PDQ). PDQ is a computerized cancer-information service maintained by the
National Cancer Institute (NCI). It offers general information about cancer, NCI’s
recommendations for standard treatment at each stage of a cancer, as well as
information about FDA-approved clinical trials. CRI makes no medical recommendations; we suggest that patients review information they receive with their physicians.
CRI provides a reference guide, the Cancer Research Institute HelpBook: What
To Do If Cancer Strikes. Its clear, eight-step format explains how to get the best
possible medical care, how to access support services, and how to approach other
20
CANCER RESEARCH INSTITUTE
matters, such as financial concerns. The HelpBook includes an extensive resource
directory listing medical facilities and other organizations that can furnish assistance.
We have also published two cancer-specific booklets, What To Do If Prostate
Cancer Strikes (see below) and Conquering Melanoma. Free copies are available by
calling 1-800-33CANCER.
Prostate Cancer Initiative CRI’s Prostate Cancer Initiative is a highly targeted
approach to the treatment of prostate cancer undertaken in partnership with corporations and other nonprofit agencies, including the American Cancer Society and
the National Prostate Cancer Coalition. In addition to funding research through the
Clinical Investigation Program, the Initiative concentrates on patient support and
education.
Patient Support and Education: CRI funded the nationalization of the American
Cancer Society’s patient support group program, Man-to-Man. It provides a forum
for men diagnosed with prostate cancer to learn about the disease in an environment that encourages them to discuss their concerns and share solutions to common problems. In fiscal 2003, CRI awarded $50,000 to the National Prostate
Cancer Coalition for the “Drive Against Prostate Cancer,” a national mobile screening and education campaign. The mobile screening unit, owned by Thor Industries,
tours the country and to date has provided more than 20,000 men with free
prostate cancer screenings. The Institute continues to build awareness through the
wide distribution of its booklet, What To Do If Prostate Cancer Strikes.
ANNUAL AWARDS
William B. Coley Award for Distinguished Research in Immunology
CRI grants the Coley Award to one or more scientists for outstanding achievements in basic immunology and cancer immunology. The award was established in
1975 in honor of Dr. William B. Coley, the acknowledged “father of cancer
immunotherapy,” whose daughter, the late Helen Coley Nauts, founded the Cancer
Research Institute.
Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research
The Institute’s Grace Award recognizes the contributions of dedicated laypersons whose leadership has had a significant impact on cancer research. The award
is named in memory of Oliver R. Grace, the founding chairman of CRI, who died in
1992.
SPECIFIC PROJECTS
CANCER RESEARCH INSTITUTE
21
July 1, 2002 - June 30, 2003
During fiscal 2003, CRI funded more than $10 million worth of training and research
with grants at 98 institutions in 22 states and 14 countries—an effort that truly knows
no boundaries.
Our congratulations go out to all recipients, along with high hopes for their productive
careers.
Predoctoral Emphasis Pathways in
Tumor Immunology
Harvard Medical School, Boston, MA
Harvey I. Cantor, M.D., and Hidde L.
Ploegh, Ph.D.
Program Coordinators
Johns Hopkins University School of
Medicine, Baltimore, MD
Drew M. Pardoll, M.D., Ph.D.
Program Coordinator
Peter MacCallum Cancer Insititute,
University of Melbourne, and Ludwig
Institute for Cancer Research,
Melbourne, Australia*
Mark J. Smyth, Ph.D.
Program Coordinator
The Rockefeller University,
New York, NY
Michel C. Nussenzweig, M.D., Ph.D.
Program Coordinator
University of Colorado Health
Sciences Center, Denver, CO
Philippa C. Marrack, Ph.D.
Program Coordinator
University of Pennsylvania,
Philadelphia, PA
Yvonne Paterson, Ph.D., M.Sc.
Program Coordinator
University of Washington School of
Medicine, Seattle, WA
Christopher B. Wilson, M.D.
Program Coordinator
Washington University School of
Medicine, St. Louis, MO
Robert D. Schreiber, Ph.D.
Program Coordinator
Weill Medical College of Cornell
University, New York, NY
Carl F. Nathan, M.D., and Alan N.
Houghton, M.D.
Program Coordinators
Immunology/Tumor Immunology
Courses
Alberto Martin, Ph.D.
Role of chromatin remodeling in Ig V
region hypermutation
Brigham and Women’s Hospital,
Boston, MA
Mary E. Keir, Ph.D.
The role of PD-1 in peripheral tolerance and tumor rejection
Carme Roura-Mir, Ph.D.
T-cell immunosurveillance of CD1cpresented dolichyl glycolipids in transformed cells
“The Third Millenium” in Immunology,
Tumor Immunology and Cancer
Research*
Moscow State University,
Moscow, Russia
Sergei A. Nedospasov, Ph.D., D.Sc.
Course Coordinator
Brown University, Providence, RI
Marc Y. Dalod, Ph.D.
Regulation of innate and adaptive
immune responses to viral infections:
Role of the cross-talk between NK cells
and APC
Winter School in Immunology
Taj Fort Aguada, India
Pramod K. Srivastava, Ph.D.
Course Coordinator
The Burnham Institute, La Jolla, CA
Shihao Chen, Ph.D.
Stucture and function of L-section
ligands
Postdoctoral Fellowships
Wilfried K. Roth, M.D.
The role of DEDD proteins in apoptosis
and cancer
Albert Einstein College of Medicine,
Bronx, NY
Peter R. Lawson, Ph.D.
Molecular basis of lipid antigen recognition by CD1 restricted NKT cells
Ziqiang Li, Ph.D.*
Role of mismatch repair in somatic
hypermutation and recombination in
B cells
California Institute of Technology,
Pasadena, CA
Yongning He, Ph.D.*
Three-dimensional EMK studies of IgG
transport by FcRn
The CBR Institute for Biomolecular
Research, Boston, MA
Stefano Casola, M.D.
Role of Epstein-Barr virus encoded
LMP1 and LMP2a proteins in an animal model for Hodgkin’s disease
22
CANCER RESEARCH INSTITUTE
Stefan Feske, M.D.
Cloning and characterization of the
gene responsible for a defect in capacitative calcium entry in patients with a
severe combined immunodeficiency
Sin-Hyeog Im, Ph.D.
Role of calcineurin/NFAT signaling in
generation and function of IL-10 producing regulatory T cells
Alexandra M. Joseph, Ph.D.
Activated notch1 expression in germinal center B cells: A potential model of
classical Hodgkin’s disease
Children’s Hospital, Boston, MA
Nava Almog, Ph.D.
Molecular mechanisms which underlie
the heterogeneity of angiogenic activity
in a tumor
Oliver R. Grace Jr. Fellowship
Columbia University College of
Physicians & Surgeons,
New York, NY
Qinglian Liu, Ph.D.*
Structural analysis of Hsp70 chaperone activity
Dana-Farber Cancer Institute,
Boston, MA
Mei-Ling Chen, Ph.D.
An animal model for investigating
immunosurveillance and immunotherapy in prostate cancer
Loralee J. Haughn, Ph.D.
Characterization of Bc1-2 and cRaf1
as effectors for notch1 in T-cell lineage
choice
Hyuk Song, Ph.D.
The role of tetraspanin, A15/TALLA-1
and CD151-like molecules in cancer
biology
Emory University, Atlanta, GA
Shane Crotty, Ph.D.
B-cell memory: Understanding the
long-lived plasma cell
Donald R. Latner, Ph.D.*
The role of cell cycle genes in CD8+
memory T-cell homeostasis
David B. Masopust, Ph.D.
Disturbing the dynamics of adaptive
immunity
Edward J. Wherry, Ph.D.
Temporal gene expression during T-cell
exhaustion and deletion
Fred Hutchinson Cancer Research
Center, Seattle, WA
Joseph N. Blattman, Ph.D.
Enhancing CD8 T-cell responses to
tumors and viruses by dominantnegative inhibition of Cbl-b function
Benjamin J. McFarland, Ph.D.
The NKG2D/MIC interaction: Initiating
an immune response against
carcinomas
Xueling Wu, Ph.D.*
Identification and characterization of
HIV-1 envelope sequences that elicit
broad neutralization antibody response
Harvard Medical School, Boston, MA
Marianne L. Boes, Ph.D.
An EGFP-class II knock-in: A new tool
for visualization of MHC class II trafficking in professional antigen
Robert E. Means, Ph.D.
Molecular mechanisms of KSHV K5
gene-mediated immune evasion
Harvard School of Public Health,
Boston, MA
Michael J. Townsend, Ph.D.
Investigating the molecular mechanisms of T cell lineage commitment:
Isolation of T-β target genes and cytotoxic T-cell specific transcription factors
Harvard University, Cambridge, MA
Jeffery D. Cruzan, Ph.D.
Detailed structural study of a transcription activator-coactivator complex: The
CBP/p300-NFκB interaction
Sarah M. McWhirter, Ph.D.
Characterization of a novel IκB kinase
complex
Yingxia Wen, Ph.D.
Mechanisms regulating the activation
of a cluster of interferon-α and -β
genes in response to virus infection
Johns Hopkins University School of
Medicine, Baltimore, MD
Camie W.Y. Chan, Ph.D.*
Development of a novel antigen-specific
immunotherapy for cancers using
genetically-modified dendritic cells generated in vivo via bone marrow transplantation of virally-transduced
hematopoietic stem/progenitor cells
Rajneesh P. Uzgare, Ph.D.
Defining the role of B7-DC, a novel
costimulatory molecule, in mediating
immune response
Joslin Diabetes Center, Boston, MA
Reinhard Obst, Ph.D.
Setting thresholds for T-cell development by regulated ZAP-70 expression
in vivo
Shannon J. Turley, Ph.D.
Defining mechanisms of autoimmune
disease initiation: Dendritic cells and
the presentation of pancreatic β-cell
antigens
La Jolla Institute for Allergy and
Immunology, San Diego, CA
Laurent Gapin, Ph.D.
Identification of the non-classical MHC
class I molecule(s) involved in the
selection of TcRαβ+ CD8αα+ intestinal
intraepithelial lymphocytes
Massachusetts General Hospital,
Boston, MA
Gabriel D. Duda, D.Md., Ph.D.
Elucidating the extent to which bone
marrow cells contribute to tumor
growth: Potential for cancer therapy
Christine J. Williams, Ph.D.
The role of ikaros and the Mi2 β NURD
chromatin remodeling complex in lymphocyte development and lymphomagenesis
Massachusetts Institute of
Technology, Cambridge, MA
Kelly M. Elkins, Ph.D.*
Analysis and design of Bcl-2 protein
interactions
Phillip David Holler, Ph.D.*
Genetic and molecular characterization
of a central tolerance defect in NOD
mice
Michael T. McManus, Ph.D.
Mechanisms of mammalian RNA
interference
McGill University, Montreal, Canada
Annie Bourdeau, Ph.D.*
Characterization of the hematopoietic
and bone marrow stromal cell defects
in T-cell protein tyrosine phosphatasedeficient mice
Memorial Sloan-Kettering Cancer
Center, New York, NY
Don M. Coltart, Ph.D.*
The development of immunologically
based cancer therapeutics via chemical synthesis
Katrina Podsypanina, M.D., Ph.D.
Role of lymph nodes in metastatic
cancer progression
CANCER RESEARCH INSTITUTE
23
Robert D. Schreiber, Ph.D.,
an Associate Director of CRI’s
Scientific Advisory Council, won the
Institute’s prestigious William B.
Coley Award in 2001 for research
substantiating the theory of cancer
immunosurveillance. He is the
Alumni Endowed Professor of
Pathology and Immunology and
professor of microbiology at
Washington University in St. Louis.
“With CRI’s help, the controversy is over:
immune cells unquestionably fight cancer.”
-Robert D. Schreiber, Ph.D.
Dori A. Thomas, Ph.D.
Identification of the molecular mechanisms responsible for TGFβ-mediated
inhibition of T-lymphocyte proliferation
Mount Sinai Hospital,
Toronto, Canada
Bruce T. Seet, Ph.D.*
Molecular and biological specificity of
Grb2-like family proteins
National Cancer Institute,
Bethesda, MD
Claudette L. Fuller, Ph.D.
Regulatory role of the actin cytoskeleton in CTL activation
National Institute of Allergy and
Infectious Diseases, NIH,
Bethesda, MD
Alex Yee-Chen Huang, M.D., Ph.D.*
Dynamic intravital imaging of tumorAPC-T-cell interactions
Hai Qi, M.D., Ph.D.*
A possible antigen-presenting role for
dendritic cells in humoral as well as
cell-mediated immunity: High-resolution
imaging analysis in vitro and in vivo
Helen C. Su, M.D., Ph.D.*
Molecular function of caspase-8 in
lymphocyte activation
New York University School of
Medicine, New York, NY
Natacha Bitton, Ph.D.
Potential of infection by DC sign, a
dendritic cell protein and its interest
as a vaccine target
Thomas O. Cameron, Ph.D.*
A comparative study of the oligomeric
state of the T-cell receptor
Arash Grakoui, Ph.D.
The role of CD+ T cells in hepatitis C
virus pathogenesis
Ontario Cancer Institute,
Toronto, Canada
Thorsten Berger, Ph.D.
In vivo analysis of ADAM10 signaling in
p53 pathways, cancer formation, and
the innate immune system
Young B. Kim, Ph.D.
Specific gene activation during Stat3mediated cellular transformation
Rhea (Rose Marie) Finnell Memorial
Fellow
Almut Dufner, Ph.D.
Identification and analysis of PTEN
regulator and effector molecules
Vuk Stambolic, Ph.D.
Molecular analysis of PTen-induced
lymphoid tumors in vivo
Woong-Kyung Suh, Ph.D.
The role of a novel B7-related molecule
B7RP2 in the immune system
Peter MacCallum Cancer Insititute,
Melbourne, Australia
Yoshihiro Hayakawa, Ph.D.*
NKT cells in anti-tumor responses:
Conductors of tumor immunity?
Princeton University, Princeton, NJ
Dapeng Zhou, M.D., Ph.D.
Natural glycolipid ligands of CD1d
molecules
The Rockefeller University,
New York, NY
Simi T. Ahmed, Ph.D.*
Molecular mechanism of Stat3mediated transformation
Xiaodi Ren, Ph.D.
Role of B-cell specific coactivator OCAB in B-cell differentiation
Evelyn B. Voura, Ph.D.
Bone marrow transendothelial migration of multiple myeloma cells
Xin Yu, M.D., Ph.D.
Functional characterization of isoforms
of a B-cell specific coactivator
The Scripps Research Institute,
La Jolla, CA
Amanda L. Gavin, Ph.D.
B-cell responses to T-independent type
2 antigen
Kaisa H. Holmberg, M.D., Ph.D.
TCR dimerization during antigen
recognition
Stanford University School of
Medicine, Stanford, CA
Erin J. Adams, Ph.D.
Structural biology of ligand recognition
by T-cell receptors
Deepta Bhattacharya, Ph.D.*
Characterization of the hematopoietic
niche
(cont’d. page 30)
“You know you’re doing something
clearly very important when you
give to CRI.”
-Anna-Maria Kellen
Our sincere gratitude goes out to the individuals, corporations, and foundations acknowledged here for their especially generous support of CRI in 2003.
While money alone doesn’t equal a “cure” for cancer, the effective immunotherapies now seen on the horizon will certainly elude our grasp without it.
We also thank the members of the Helen Coley Nauts Society, also acknowledged on the following pages; they are helping to safeguard our future work by
naming the Institute as the beneficiary of a bequest or planned gift.
Anna-Maria Kellen and her
husband, Stephen, Co-Chairman
of the international banking firm
Arnhold and S. Bleichroeder
Holdings, Inc., are two of New
York City’s most generous
philanthropists. Mrs. Kellen has
served as a CRI Trustee for more
than 40 years, and received the
2003 Oliver R. Grace Award.
ESPECIALLY GENEROUS DONORS
CANCER RESEARCH INSTITUTE
Mr. and Mrs. Martin J. Bergin
Coley Pharmaceutical Group
Michael Berkman and Randi Ribakove
Communicator Inc.
The Estelle Abas Trust
Mr. and Mrs. Howard P. Berkowitz
Community Hearing Instruments III
Abbott Laboratories Fund
The Judy and Howard Berkowitz
Concern Foundation
Major Donors
Mr. and Mrs. Richard J. Adler
Foundation
Cliff P. Connery and Maryanne Friedel
The Altschul Foundation
Berlex Laboratories, Inc.
Mr. and Mrs. John J. Connor
Edith M. Amateau
Mr. and Mrs. Edgar R. Berner
Lottie M. and Charles H. Cook
American Express Company
Bernstein Investment Research and
Corporate Risk Solutions, LLC
American Legacy Foundation
Management
Madeleine G. Corson
Amgen Inc.
Edith C. Blum Foundation, Inc.
Daniel Cripe
A. W. Anderson Foundation
Tor Boswick
Frances L. and Edwin L. Cummings
E. M. Anderson Foundation
Steven Bowman
Kathleen C. Andrews
Estate of Barbara Brown Boyer
Mr. and Mrs. Maurice J. Cunniffe
Anonymous (10)
Mr. and Mrs. Richard S. Braddock
Mr. and Mrs. John P. Curran
Michael Anthony
Mr. and Mrs. Oren Bramson
Mr. and Mrs. John R. Curtis, Jr.
Anthony For Men L.L.C.
Mr. and Mrs. Timothy J. Brennan
Mr. and Mrs. Rodd Dalinka
Antigenics LLC
Mr. and Mrs. Conrad L. Bringsjord
Mr. and Mrs. Stuart P. Davidson
Aon Foundation
Bristol-Myers Squibb Company
Richard M. DeMartini and Jennifer L.
Nancy Arena
Broadgate Consultants, Inc.
The Atlantic Philanthropies
Brown Investment Advisory & Trust
Aureole Investment, L.P.
Company
Memorial Fund
Brorsen
DeMartini Family Foundation
Burton & Beatrice Dermer Family
Foundation, Inc.
Avon Foundation
John C. Bruce
Peter Axelrod & Associates, P.C.
Mr. and Mrs. Michael C. Buchanan
Mr. and Mrs. Philip Desantis
Mr. and Mrs. Carter F. Bales
Llewellyn Burchell Charitable Trust
Mr. and Mrs. Glenn J. DeSimone
Alissa Beth Bander Memorial
Mr. and Mrs. Charles L. Burnett
John W. Dickey
Mr. and Mrs. John P. Callahan
Rita and Harold Divine Foundation
Bank of America
Ruth Camp Campbell Foundation
Helen and Bruce Dixon
Banta Direct Marketing Group
Cardinal Health Healthcare Marketing
Nestor Dominguez
Foundation, Inc.
Joseph M. Barber
Services
Barclays Bank, PLC
Estate of Pandora Rudland Carroll
The James E. and Jacob A. Barkey
Russell L. Carson
Lynn Trunz Dominick
Robert Lee Douglas and Elizabeth A.
Strode
John and Pamela Casaudoumecq
Mr. and Mrs. Richard C. Dresdale
Mr. and Mrs. Kenneth Barmore
The Cayuga Foundation
Cathy Duffy
The Florence & Ben Barrack
Mr. and Mrs. Christopher E. Chalsen
James Dunne
Chapdelaine Corporate Securities &
Eckerd Corporation Foundation
Memorial Fund
Foundation Inc.
Mr. and Mrs. Michael G. Barrett
Co.
John Eckerson
The Barrington Foundation
Charina Foundation, Inc.
Estate of Dorothy M. Eiser
Rose Barrow
Russell and Katherine Charlton
Richard A. Eisner
Brian L. Bartlett
Citigroup Global Markets, Inc.
Eli Lilly and Company
Estate of Etta Baum
David C. Clapp Foundation
Mrs. Richard B. Englund
Bear, Stearns & Co., Inc.
Clayton, Dubilier & Rice, Inc.
Essence Communications, Inc.
Timothy P. Beaulac
Cline, Davis & Mann, Inc.
Estron Chemical, Inc.
Everett A. Bell
William H. Coffee Trust
Daniel Eule
Estate of Germaine Benesch
Mr. and Mrs. Geoffrey O. Coley
Exxon Mobil Corporation
25
26
CANCER RESEARCH INSTITUTE
Estate of Mary S. Fadeley
Green Charitable Foundation, Inc.
Kaye Scholer LLP
Sean Fahey
Green Family Foundation
Kekst and Company Incorporated
FannieMae
Joyce Green Family Foundation
Kelco Landscaping, Inc.
Mr. and Mrs. Thomas M. Farley, Jr.
GreenPoint Foundation
Anna-Maria & Stephen Kellen
Mr. and Mrs. Vincent Farrell, Jr.
Christine Gunner
Fashion Bug
Mary Gurster
William M. Kelly
Andrew and Mindy Feldman
Haffenreffer Family Fund
Estate of Blanche C. Kelly
Mr. and Mrs. Carlos A. Ferrer
Hagedorn Fund
Rene M. Kern
Ferrer Freeman & Company LLC
Philip J. Hahn
Estate of Elsie E. Kiel
Nazareth Festekjian
Bruce D. Haims and Judy Jackson
David B. Kinney
Jerrold & Sally Fine Foundation, Inc.
Neita Harrigan
F.M. Kirby Foundation, Inc.
Warren J. Finnell
Harvest Charities
Mr. and Mrs. David M. Kittay
Ramin Firoozye
Estate of Margaret Hayman
Mr. and Mrs. Michael Klein
Mr. and Mrs. John B. Fitzgibbons
Mr. and Mrs. Donald B. Hebb, Jr.
Robert E. Kling
Christopher Fitzmaurice
Mr. and Mrs. William Heinzerling
Mark Kopcha
Fitzpatrick, Cella, Harper & Scinto
Estate of Fredrick Charles Henne
KPMG LLP
Fleet Bank
The Carl J. Herzog Foundation
Estate of Sidney G. Ladue
Foote Cone & Belding
Edward A. Hewett and Margaret A.
C. Linda Lambert 2001 Separate
Mr. and Mrs. William E. Ford III
Heyob
Foundation
Property Trust
Ford Foundation
Mr. and Mrs. John Howitt
Mr. and Mrs. Leigh R. Lasky
Mr. and Mrs. James A. Forese
Robert Huffman
Mr. and Mrs. Carey F. Lathrop
Max & Clara Fortunoff Foundation
ICON Clinical Research, Inc.
Gregory P. Lee
Anthony Frangione
Pat Ihlenburg
James B. Lee, Jr.
Freygish Foundation
International Equity Advisors LLC
The Florence & Edgar Leslie
Fribourg Family Foundation
J.V. Sports
Gambrell Family Foundation
Mr. and Mrs. Charles W. Jackson
Mr. and Mrs. Gary J. Gartner
Mary L. Jacob
Lawrence M. Gelb Foundation, Inc.
The Benjamin Jacobson and Sons
General Atlantic Partners
Foundation
CharitableTrust
James Annenberg Levee Charitable
Foundation
Les Levi
Anne Boyd Lichtenstein Foundation
Estate of Mildred Gentry
Mr. and Mrs. Robert J. Jacobson
Mr. and Mrs. Rich Lightburn
Gibbs & Associates
The Jesselson Foundation
Vincent S. Lima
Regina Gilmour Charitable Remainder
Jockey Hollow Foundation, Inc.
Fran Liner Kupferman
Trust
Margaret Ann Johnson
The Bari Lipp Foundation
Mr. and Mrs. Jay T. Glassman
Mr. and Mrs. Thomas S. Johnson
Lord & Taylor
Mr. and Mrs. Donald J. Gogel
Johnson & Johnson
L'Oreal USA
Laurie and Jeffrey Goldberger
JPMorgan Chase & Company
Richard Ray Loucks and Ruth M.
Philip Goldblatt Charitable Trust
The J.P. Morgan Chase Foundation
John G. & Jean R. Gosnell Foundation,
Inc.
Matching Gift Program
Loucks Fund
Mr. and Mrs. Leroy W. Lovelidge III
Estate of Doris Kabat
Mr. and Mrs. Alexander P. Lynch
Janet Maureen Grace Committeeship
David Kampff
Sally & Alex Lynch Fund
Mrs. Oliver R. Grace
Merherwan K. Kandawalla
Mrs. Eleanor D. MacCracken
Oliver R. Grace Charitable Foundation
Robert S. Kaplan
The Maher Family Foundation
Mr. and Mrs. Robert M. Grace
The Kastory Family Foundation
Mr. and Mrs. Tom Maheras
Granite Broadcasting Corporation
Marion Esser Kaufmann Foundation
Estate of Henrietta Malbin
CANCER RESEARCH INSTITUTE
Mr. and Mrs. Ronald M. Mateo
Mr. and Mrs. Joseph C. O'Connor
Mr. and Mrs. Julian H. Robertson, Jr.
Estate of Margaret Mazzey
The O'Donnell Iselin Foundation, Inc.
The Robertson Foundation
The MBNA Foundation
Lloyd J. Old, M.D.
Mr. and Mrs. Ralph W. Rose
Lynn Glenn McAtee
Mr. and Mrs. Stephen Oplinger
Eric Rosen
Helen G. Spencer McDermid
Ortho Biotech
Lief D. Rosenblatt
Mr. and Mrs. Patrick J. McGrath
Peter B. Orthwein
David Asher Rosenstein
Mr. and Mrs. Robert M. McKeon
Paul and Anna Oschwald Trust
Mr. and Mrs. Jonathan Roth
McMullan Family Fund
Mr. and Mrs. John Ostrander
Mrs. Edmond J. Safra
Medical Action Communications, USA
Estate of Marjorie W. Packwood
The Sage Foundation
Medicus Group International, Inc.
Debbie Pappas
Mr. and Mrs. Daniel J. Salmon
Thomas G. and Andrea Mendell
The Partridge Foundation
Salomon Smith Barney
Andrew M. Paul Family Foundation
Stanley and Jane Sapery
Mr. and Mrs. Eugene Mercy, Jr.
Peale Foundation
Mr. and Mrs. Christopher J. Sarkis
Estate of Nancy J. Merkel
George W. Peck IV
Jack Scanlon
Merrill Lynch & Co., Inc.
PerkinElmer Foundation
Mr. and Mrs. Michael E. Schultz
Mr. and Mrs. Michael Meyers
Jeffrey A. Perlowitz
Mr. and Mrs. Henri Axel Schupf
Millennium Pharmaceuticals, Inc.
Steve Peterson
The Edith M. Schweckendieck Trusts
Mr. and Mrs. Mark G. Miller
Mr. and Mrs. Leland A. Peyser
Estate of Harold Bend Sedgwick
Robert Miller
Pfizer Inc
Gillian Z. Segal and Peter Lattman
Mr. and Mrs. Robert K. Miller
David C. Pichler
Tasha Seitz
Rory Millson and Linda E. Rodd
Pielsticker Charitable Lead Annuity
Select Equity Group Foundation
Foundation
Estate of Alex Mitchell
Trust
Michael Charles Sharp
The Ambrose Monell Foundation
Estate of Harriet-Anne Pierson
Mr. and Mrs. Donald Shaw
Montgomery, McCracken, Walker &
Estate of Dorothy Plumb
Eric P. Sheinberg Foundation
Estate of Nick J. Pokea
Mr. and Mrs. David M. Shepherd
Mr. and Mrs. Robert A. Posner
Renee and Irwin Shishko
Mr. and Mrs. Edwin Damron Poulton
Shubert Foundation, Inc.
Sarah Mott
Price Family Foundation
Estate of Belle V. Silverstein
Estate of Alexander Munchweiler
PriceWaterhouseCoopers
Simpson Thacher & Bartlett
Robert A. Murray
Estate of Dorothy S. Pritchard
The Simpson Foundation
Mutual of America
Joseph J. Provenzano
Linda and Stephen L. Singer Fund
Gregory R. Myers
Mr. and Mrs. Jeremy Purbrick
Estate of Jean V. Sirles
Naomi Myers
John E. Purcell
Mr. and Mrs. Ernest B. Smith
Carey Nachenberg
Mr. and Mrs. James B. Quigley
Mr. and Mrs. James C. Smith
The Nash Family Foundation, Inc.
Mr. and Mrs. Matthew Quigley
Estate of Ruth Sneve
Sergei A. Nedospasov, Ph.D., D.Sc.
The Raether Family 1985 Charitable
Soros Fund Charitable Foundation
Rhoads, LLP
Morgan Stanley Dean Witter
Foundation
The New York Academy of Medicine
Trust
Mark Stein
Mr. and Mrs. Matthew Nimetz
Random Real Estate
Mr. and Mrs. James Stern
Estate of Geneva W. Nolen
James Ransohoff, Jr.
Mr. and Mrs. Richard B. Stolley
Mr. and Mrs. Jacques C. Nordeman
Dr. Barbara Ray
Estate of Myrtle B. Summers
Novartis Oncology
Roma Reavis-Wehde
Estate of John J. Supon
Ardavan Nozari
The Reese Charitable Remainder
Surefire Marketing, Inc.
Estate of Dorothy B. Nurick
Harry A. & Margaret M. Oak
Charitable Lead Trust
Trust
Swansea Holy Ghost Brotherhood
Mr. and Mrs. James Remick
Mr. and Mrs. Josh Tane
Mr. and Mrs. Brian Riano
Mr. and Mrs. Mitchell J. Taube
27
28
CANCER RESEARCH INSTITUTE
Lee Asher
Betty Disbrow
Belle Asherman
Adelaide J. Dodge
Mr. and Mrs. George D. Thurston
Else Baier
Blanche Elizabeth Eckerts
Time Life, Inc.
Olga Baker
Dorothy M. Eiser
Krista Tommarello
Marion D. Balen
Ruth Engelberg
Mr. and Mrs. Remy W. Trafelet
Jeanne E. and Jacob A. Barkey
Nathan Epstein
Mr. and Mrs. Robert S. Trump
Mr. and Mrs. Kenneth Barmore
Max G. Eriksen
Tullett & Tokyo Investment Corp.
Florence and Ben Barrack
Juanita M. Evans
UBS Investment Bank
Rose Barrow
Mary S. Fadeley
Ueberroth Family Foundation
Etta Baum
Helen Jean Falk
Union Pacific
Frank L. Bell
Herbert Lynn Fann
The Uplands Foundation
Germaine Benesch
Florence A. Fanning
Nancy and Jim Utaski
William A. Berkey
Carlos A. Ferrer
Estate of Zelda M. Uthe
Herta J. Bernstein
Adelaide E. Ferris
Mr. and Mrs. Jeffrey K. Valentine
Grace M. Bishop
Paul Fierro
Vance Van Dine
John Bittel
Clay Frazier
Steven R. Victorin
Guy Bjorkman
Alice M. Fried
Antone L. Vinelli Irrevocable Trust
Leslie J. Blain
Zoltan Galdi
Mr. and Mrs. John Vissichio
Lawrence H. and Nancy E. Bonander
Salvador Garcia
Thomas M. Von Lehman and
Mary Borbeck
Stella Gentile
Wade F.B. Thompson Charitable
Foundation, Inc.
Robina C. Bouchard
Mildred Gentry
Steve Wagman
Barbara Brown Boyer
Penelope M. Georgiadis
WellPoint Health Networks
Lucille Brents
Janet Gifford
Mr. and Mrs. Robert M. Wepfer
Victor E. Broll
Regina Gilmour
Mr. and Mrs. William T. Whamond
Albert N. Brooks
Eleanor Goldberg
Gerald I. White Fund
Minnie E. Brown
Norman Gottlieb
Whiting Foundation
Virginia Bruner
Joseph Junior Greathouse
Estate of Saul J. Wiener
Alfred R. Brunner
Jeanine Hair
Mr. and Mrs. Richard Wilkes
Cleo F. Bush
Nelle B. Haire
Wyeth
Joy Biggs Buttle
Loretta D. Hardy
Mr. and Mrs. Thomas M. Yamin
Tracy Campbell
Evelyn H. Harris
Stephen Yegelwel
Angela Carbone
Ottis C. Harris
Estate of Marion E. Youngberg
Alfred Carlucci
Helaine T. Harrison
Mr. and Mrs. Ronald F. Zampolin, Jr.
Julia Carlucci
James Leon Hawkins
Peter Zdazenski
Pandora Rudland Carroll
Margaret Hayman
Mr. and Mrs. Ronald M. Zimmerman
Donald O. Carswell
Virginia Hemme
Melba Case
Fredrick Charles Henne
William H. Coffee
Senora Henry
Gwendolyn Colburn
Kay Hilton
Lottie M. and Charles H. Cook
Grace M. Humphrey
Estelle Abas
Eleanor H. Cromley
Fred W. and Idell E. Iltner
Peter Adams
Vincent D'Amico
Ruby R. Jankiewicz
Frederick Allard
Annabelle L. Danzig
Eldon and Lynn Jasper
Ruth Ascher
Aileen Adele Delong
Warren R. Jecklin
Rex and Virginia Ashdown
Emma Deters
Doris M. Johnson
Margaret M. Good
Helen Coley Nauts Society
CANCER RESEARCH INSTITUTE
Doris Kabat
Ezilda Michel
Renee and Irwin Shishko
Bertha E. Kaufman
Helen T. Middleton
Katherine U. Silva
Samuel Kay
Ruth Miller
Belle V. Silverstein
Blanche C. Kelly
Alex Mitchell
Augusta Simon
Elsie E. Kiel
Janet P. Morgan
Roma Sinclair
Theresa A. Kiely
Stella Moss
Estelle Singer
Hilda Kirson
Alexander Munchweiler
Jean V. Sirles
Ruth Klotz
Judith K. Murphy
Paul Slat
Anne Koch
Kathryn T. Murphy
Catherine M. Smith
Josephine M. Krska
Thomas P. Murray
Mr. and Mrs. Ernest B. Smith
Murray Kupferman
Thomas Murry
Ruth Sneve
Rose Lachow
Naomi Myers
Fred E. Spencer
Sidney G. Ladue
Alice A. Nauts
W. M. Sprenger
Anna Lagstein
Rose E. Nelson
Brenda M. St. James
C. Linda Lambert
Freda E. Newton
Gerald J. Steinberg
Ann Lancet
Geneva W. Nolen
Leopold Steindecker
Marguerite Landis
Dorothy B. Nurick
Daniel B. Stern
Caryl Lou Langford
Harry A. and Margaret M. Oak
Myrtle B. Summers
Elizabeth S. Larkin
Michele A. Ognibene
John Supon
James F. Levens
Lauri Olsen
Carl E. Thomas
Betty Lou Levin
Alice Orlich
George C. Thomas, Jr.
Beatrice Levy
Paul and Anna Oschwald
Overton Arnold Thompson
Johanna Loeb
Lilly E. Pace
Viola Mae Thompson
Peter Lommen
Marjorie W. Packwood
John R. and Anita Timmel
Delia Luna
Andrew Reid Paton
Carola S. Trier
Kay Lungo
Frederick V. Payne
Zelda M. Uthe
Norma Lyon
Nancy Elizabeth Pease
Josephine S. Villeman
Eleanor D. MacCracken
Rose Perry
Antone L. and Myrtle H. Vinelli
Emilie Machalinski
Agnes Phelps
Anne D. Vinton
Catriona Macleod
John Piercy
Ethel A. Wagner
David Madsen
Harriet-Anne Pierson
David Walker
Henrietta S. Malbin
Dorothy Plumb
Julia Walz
William S. Mardenborough
Nick J. Pokea
Irene M. Watkins
Aljoe Martin
Despina Poulos
Dorothy Waugh
Isolde K. Martin
Mrs. P. Prasad
Albert L. and Ione A. Weickert
Raleigh L. Martin
Dorothy S. Pritchard
Vera White
Evelyn Masdonati
Helen Relkin
Saul J. Wiener
Mildred G. Matz
Floris J. Renk
Ora Brown Windle
Margaret Mazzey
Veronica A. Rose
Nettie Wright
Michael I. McBride
Susan Rosenberg
Ethel R. Young
Annette McDonald
Hedwig Salzer
Marion E. Youngberg
J. Donald McKinney, Jr.
Lydia B. Scannell
Gloria Zaino
Jan Mears
Helen R. Schutt
Grace Muriel Mecchi
Ruth Schwartzman
Nancy Jeanne Merkel
Rev. Harold Bend Sedgwick
29
30 SPECIFIC PROJECTS (cont’d.)
Camilla Forsberg, Ph.D.
Chromatin remodeling in stem-cell
differentiation
Emmanuel Niels Treiner, Ph.D.*
Mechanisms of natural killer cells selftolerance
Martha S. Jordan, Ph.D.
The role of SLP-76 domains in thymocyte development and T-cell function
Tara Maureen C. Hornell, Ph.D.
GM-CSF-mediated regulation of class II
MHC antigen presentation in human
monocytes
Xingxing Zang, Ph.D.
PD-1 mediated inhibition in T-cell
responses: Molecular mechanisms and
manipulation in tumor immunotherapy
Wei-Xing Zong, Ph.D.
Roles of c-Myc and Akt protooncogenes in lymphocyte metabolism
and apoptosis
Johannes B. Huppa, Ph.D.
Defining the mechanism that links
ligand-recognition by αβ TCR to T-cell
activation
University of California,
Los Angeles, CA
Caius G. Radu, M.D.
The role of the lysophospholipid receptor G2A in immunological tolerance
University of Texas Southwestern
Medical Center at Dallas, Dallas, TX
Gaya K. Amarasinghe, Ph.D.
Structural basis for regulation of guanine nucleotide exchange activity of the
DBL homology domain from the protooncogene product VAV
Ji-Yun Kim, Ph.D.
Rho GTPases in chemattractantstimulated adhesion
Michael S. Kuhns, Ph.D.
TCR-mediated events in immunological
synapse formation
Karina L. McQueen, Ph.D.
Human natural killer cell receptor
reconstitution and alloreactivity following allogeneic bone marrow
transplantation
Sang-Ho Park, Ph.D.
Cross-regulation between the Wnt
signaling and T-cell activation
University of California, San Diego,
La Jolla, CA
Carl S. Goodyear, Ph.D.
Superantigen induced cell death in
leukemic B cells
Li-Chung Hsu, Ph.D.
The mechanism of IKK/NF-κB and p38
MAPK signaling pathways synergizing
to suppress apoptosis in activated
macrophages
University of Virginia,
Charlottesville, VA
Donald R. Drake, Ph.D.
Mechanisms of incomplete CD8+ lymphocyte activation
Zhi-Wei Li, Ph.D.
The role of IKK-β in lymphoid leukemia
and lymphoma
Kevin L. Legge, Ph.D.*
Role of respiratory dendritic cells in
the adaptive immune response to pulmonary infections
Achal M. Pashine, Ph.D.
Accessory molecules in the class II
presentation pathway: Structure and
function
University of California,
San Francisco, CA
Victoria L. Crotzer, Ph.D.
The role of clathrin in T-cell receptor
internalization and MHC class I target
recognition on tumor cells
University Hospital Basel,
Basel, Switzerland
Mark A. Daniels, Ph.D.*
Defining the affinity threshold for positive and negative T-cell selection
Tianhe Sun, Ph.D.*
The roles of NK activating receptors
and their ligands in host defense
University Hospital Zurich,
Zurich, Switzerland
Nicola Harris, Ph.D.
Allergy and the gut
University of California, Berkeley, CA
Samantha Jane Allen, Ph.D.*
The structure and function of
chemokine receptors
Philippe Bousso, Ph.D.
Dissection of thymocyte selection
events at the single cell level
Nadine C. Fernandez, Ph.D.
Self tolerance of natural killer cells:
The role of NK hyporesponsiveness
Tsvetelina P. Pentcheva, Ph.D.
Mechanism of regulation of T-cell
function by CD28 and CTLA-4
David M. Morgan, Ph.D.
Mechanism of WASP activation by
Cdc42
University of Chicago, Chicago, IL
Yuval Sagiv, Ph.D.*
Glycolipid antigen presentation by CD1
molecules: Role of endosomal saposins
University of Cologne,
Cologne, Germany
Markus Müschen, M.D.
Rescuing pre-apoptotic germinal center
B cells: The role of the Epstein-Barr
virus in early steps of the pathogenesis
of Hodgkin’s disease
University of North Carolina at
Chapel Hill, Chapel Hill, NC
Raquel Sitcheran, Ph.D.
Investigating the role of NF-κB in cell
differentiation and oncogenesis
University of Pennsylvania,
Philadelphia, PA
Ezequiel M. Fuentes, Ph.D.
Regulation of B-cell development by the
BCR components of Ig α and Ig β
Angela L. Zarling, Ph.D.
Phosphorylated peptides associated
with MHC molecules identification,
immunogenicity and use as tumor
antigens
Washington University School of
Medicine, St. Louis, MO
Eric Sean Barton, Ph.D.
Role of host antiviral molecules in
murine gammaherpesvirus 68
pathogenesis
Jack D. Bui, M.D., Ph.D.
The role of natural killer cells in tumor
surveillance and rejection
Hiroaki Ikeda, M.D., Ph.D.*
Identification of novel tumor-specific
antigens in fibrosarcomas derived from
RAG2-/- immunodeficient mice
John Hans Old and Edna Alice Old
Memorial Fellow
Olga V. Naidenko, Ph.D.
Stuctural basis of promiscuous ligand
recognition by the natural killer cell
activating receptor NKG2D
Lyse A. Norian, Ph.D.*
Tumor progression and aging:
Combined effects on the anti-tumor
response
CANCER RESEARCH INSTITUTE
Nigel D.L. Savage, Ph.D.
CD43: A critical regulator of T-cell
motility and activation
Whitehead Institute for Biomedical
Research, Cambridge, MA
Matthew G. Guenther, Ph.D.*
Dissection of the NF-κB transcriptional
regulatory network in human
macrophages
I-hung Shih, Ph.D.
Tiny regulatory RNAs in hematopoiesis:
A possible link to hemotological
diseases
Emily C. Walsh, Ph.D.*
Genetic analysis of host susceptibility
to human immunodeficiency virus and
acquired immunodeficiency syndrome
Yanping E. Lu, Ph.D.
Mechanistic studies and antiviral functions of interferon-inducible human
guanylate-binding proteins
Yehuda Matza, Ph.D.*
The role of a novel giant proteinAHNAK2 in calcium signaling in the
immune system
Charalambos G. Spilianakis, Ph.D.*
Protein and chromatin modifications
required for the expression of the IL-4
gene during TH1/TH2-cell
differentiation
Yisong Y. Wan, Ph.D.*
Characterize the roles of Smad4 in
T-cell function
31
Brigham and Women’s Hospital,
Boston, MA
D. Branch Moody, M.D.*
Activation of human dendritic cells for
CD1-mediated lipid antigen presentation to T cells
California Institute of Technology,
Pasadena, CA
Jose Alberola-Ila, M.D., Ph.D.
Analysis of the signals that control T
cell fate determination
Columbia University College of
Physicians & Surgeons,
New York, NY
Raphael A. Clynes, M.D., Ph.D.
Indentification of cellular effectors and
molecular mechanisms of FcRmediated ADCC in vivo
Investigator Awards
The Wistar Institute, Philadelphia, PA
Sandra E. Lavens-Phillips, Ph.D.
Regulation of Epstein-Barr virus reactivation in B lymphocytes
Yale University School of Medicine,
New Haven, CT
Ona E. Bloom, Ph.D.*
Function of neuronal proteins at the
immunological synapse
Aimin Jiang, Ph.D.*
E-cadherin/catenin signaling and the
control of dendritic cell function
Koichi Kobayashi, Ph.D.
Analysis of the CARD carrying kinase
gene in vivo
Baylor College of Medicine,
Houston, TX
Jin Wang, Ph.D.
Roles of caspase-10 in initiating
apoptosis signaling
Zheng Zhou, Ph.D.
Recognition and phagocytosis of
apoptotic cells
Beth Israel Deaconess Medical
Center, Boston, MA
Masayuki Noguchi, M.D., Ph.D.
Molecular characterization of protooncogene TCL1 as an Akt kinase coactivator
Danila Valmori, Ph.D.
Use of MHC class I/peptide multimers
incorporating tumor antigen-derived
peptides for dissecting the interactions
between MHC/tumor antigen complexes and specific T-cell receptors
Dartmouth Medical School,
Hanover, NH
Charles Sentman, Ph.D.
NK-cell recognition and activation
against tumor metastasis
“We see very encouraging immune
responses in the trials supported by CRI.”
Ellen Puré, Ph.D., an Associate
Director of the Scientific Advisory
Council and Chairman of the
Fellowship Committee, also
sits on the committee that
selects the CVC participants and
reviews and monitors the program’s clinical trial protocols.
She is a professor at the Wistar
Institute in Philadelphia and
Director of the Office of Academic
Review at the Ludwig Institute for
Cancer Research.
-Ellen Puré, Ph.D.
32
CANCER RESEARCH INSTITUTE
CRI-funded scientist Ian Frazer,
M.D., developed the methods
used to create a new vaccine that
could prevent nearly half of all
cases of cervical cancer, which
kills nearly 300,000 women each
year. He is Director of the Center
for Immunology and Cancer
Research, Princess Alexandra
Hospital, at the University of
Queensland, Australia.
“This new vaccine that prevents cervical
cancer grew out of research funded by CRI.”
-Ian Frazer, M.D.
Deutsches Krebsforschungszentrum,
Heidelberg, Germany
Stefan Eichmüller, Ph.D.
Characterization and evaluation of a
new tumor-specific antigen for immune
therapy of cutaneous T-cell lymphoma
and other malignancies
Elaine R. Shepard Memorial
Investigator
Duke University Medical Center,
Durham, NC
Tannishtha Reya, Ph.D.*
Control of hematopoietic stem-cell
development
Fred Hutchinson Cancer Research
Center, Seattle, WA
Cassian Yee, M.D.
Augmentation of immune response to
melanoma
Karolinska Institute,
Stockholm, Sweden
Petter Höglund, M.D., Ph.D.
Dissecting the mechanisms of natural
killer cell tolerance
Krankenhaus Nordwest,
Frankfurt, Germany
Elke Jäger, M.D.
New SEREX-defined cancer antigens,
T-cell responses and implications for
specific cancer immunotherapy
Partridge Foundation Investigator
Ludwig Institute for Cancer
Research, Lausanne, Switzerland
Frédéric Lévy, Ph.D.
Factors influencing the generation of
CTL-defined peptide tumor antigens
Ludwig Institute for Cancer
Research, New York, NY
Ali O. Güre, M.D., Ph.D.
CT antigens in cancer: Mechanism of
SSX gene expression and identification
of genes with restricted tumor
expression
Libby Bartnick Memorial Investigator
Mayo Clinic, Rochester, MN
Daniel D. Billadeau, Ph.D.
Regulation of anti-tumor immunity by
Rho-GTPase effector pathways
Mount Sinai School of Medicine,
New York, NY
Patricia Cortes, Ph.D.
In vitro V(D)J recombination: Signal
and coding joint formation during inversional recombination
Gwendalyn J. Randolph, Ph.D.
Differentiation and migration of
monocyte-derived dendritic cells and
their role in immunity: Comparison to
other dendritic cell subsets
Northwestern University,
Evanston, IL
Theodore S. Jardetzky, Ph.D.
Structural studies of cell surface
receptors of the immune system
Oregon Health & Science University,
Portland, OR
Qing Ching Chen, M.D.
Receptor editing in self-reactive B
lymphocytes: A mechanism of
autoimmunity
The Rockefeller University,
New York, NY
Madhav Dhodapkar, M.D.
Optimizing immune responses to dendritic cells in humans
The Scripps Research Institute,
La Jolla, CA
Christoph Rader, Ph.D.
Generation and humanization of rabbit
monoclonal antibodies for therapeutic
targeting of the tumor vasculature
Partridge Foundation Investigator
Stanford University School of
Medicine, Stanford, CA
K. Christopher Garcia, Ph.D.
Structural studies of the interleukin-6
receptor complex
University of Chicago, Chicago, IL
Ioannis A. Aifantis, Ph.D., M.Sc.*
The BCL-2 family member A1 as a regulator of T-cell survival and
transformation
Guido Franzoso, M.D., Ph.D.
The control of apoptosis by NF-κB
University of Massachusetts Medical
Center, Worcester, MA
Cynthia A. Chambers, Ph.D.
Immunoregulation of CTLA-4-/- T cells
in vivo
Francis Ka-Ming Chan, Ph.D.*
Analysis of TNF receptor signaling in
health and disease
University of Michigan, Ann Arbor, MI
Malini Raghavan, Ph.D.
Molecular interactions in the MHC
class I antigen presentation pathway
CANCER RESEARCH INSTITUTE
University of Oxford,
Oxford, United Kingdom
Vincenzo Cerundolo, M.D., Ph.D.,
MRCPath.
Processing and presentation of
melanoma CTL epitopes
University of Washington School of
Medicine, Seattle, WA
Mark Bix, Ph.D.
Regulation of cytokine gene expression
Chen Dong, Ph.D.*
Regulation of immune responses by
novel costimulatory molecules
Washington University School of
Medicine, St. Louis, MO
Robert H. Arch, Ph.D.
TRAF-mediated signaling pathways regulating tumor cell apoptosis
Barry P. Sleckman, Ph.D.
Regulation of T-cell receptor gene
rearrangement
Clinical Investigation Program
Cancer Vaccine Collaborative
Columbia Presbyterian Medical
Center, New York, NY
Kyriakos P. Papadopoulos, M.D.†, and
Charles Hesdorffer, M.Med.
(1) Phase I study of NY-ESO-1 peptide
immunization with GM-CSF of patients
with tumors expressing NY-ESO-1 or
LAGE-1; (2) A phase I study of peptidebased vaccine therapy in patients with
high-risk or metastatic melanoma
†
Anna-Maria Kellen Clinical Investigator
Krankenhaus Nordwest,
Frankfurt, Germany
Elke Jäger, M.D.
Pilot study of immunization with
ProteinD MAGE-3/His and/or NYESO-1 protein combined with CpG
7909 in patients with tumors expressing MAGE-3 and/or NY-ESO-1 and/or
LAGE-1
Ludwig Institute for Cancer
Research, New York, NY*
Gerd Ritter, Ph.D.
Development, manufacture, and characterization of mixed bacterial vaccine
(Coley’s toxin) for clinical reevaluation in
patients with cancer
Mayo Clinic & Foundation,
Rochester, MN*
Svetomir Markovic, M.D., Ph.D.
Dose finding study of aerosolized NYESO-1 peptide vaccine with/without
GM-CSF administered as adjuvant therapy following complete tumor resection
Memorial Sloan-Kettering Cancer
Center, New York, NY
Harry Herr, M.D., Dean F. Bajorin,
M.D., Padmanee Sharma, M.D.,
Ph.D., Sacha Gnjatic, Ph.D.
NY-ESO-1 protein immunization of postcystectomy patients with transitional
cell carcinomas of the bladder expressing NY-ESO-1 or LAGE-1 antigen
Jakob Dupont, M.D.
Phase I study of NY-ESO-1b peptide
plus Montanide in patients with ovarian, primary peritoneal, or fallopian
tube cancer expressing NY-ESO-1 or
LAGE-1
Robert Maki, M.D., Ph.D.
A phase II study of anti-CTLA4 antibody
in advanced synovial sarcoma patients
with NY-ESO-1 or LAGE-1 expressing
tumors
Mie University School of Medicine,
Mie, Japan*
Hiroshi Shiku, M.D.
(1) Phase I trial of immunization with
HER2-derived peptide in HLA-A2402
patients with HER2-expressing cancers
of the breast, ovary, stomach or lung;
(2) Immunization with cholesteryl
hydrophobized polysaccharide (CHP)HER2 protein complex in HLA-A2402positive patients with HER2-overexpressing cancers
Mount Sinai School of Medicine, New
York, NY
Anna C. Ferrari, M.D.
Pilot study of immunization with
ProteinD MAGE-3/His and NY-ESO-1
protein combined with CpG 7909 in
patients with high-risk stage D-1 or
advanced prostate cancer expressing
MAGE-3 and/or NY-ESO-1 and/or
LAGE-1
New York University Cancer Institute,
New York, NY
Nina Bhardwaj, M.D., Ph.D., Steven
Burakoff, M.D., and Susan Talbot,
M.B.B.S.*
A randomized controlled trial of
melanoma treatment: Comparison of
dendritic cells versus QS-21 as adjuvants to stimulate anti-tumor immunity
Okayama University Medical School,
Okayama, Japan*
Eiichi Nakayama, M.D.
NY-ESO-1 protein immunization of
patients with tumors expressing NYESO-1 or LAGE antigen
33
Roswell Park Cancer Institute,
Buffalo, NY
Kunle Odunsi, M.D., Ph.D.
(1) A pilot clinical trial of NY-ESO-1DP4
p157-170, a peptide of potentially dual
MHC class I and class II specificities, in
patients with epithelial ovarian, fallopian tube or primary peritoneal carcinomas whose tumors express NY-ESO-1
or LAGE-1; (2) Phase I study of recombinant vaccinia-NY-ESO-1 and recombinant fowlpox-NY-ESO-1 in patients with
epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose
tumors express NY-ESO-1 or LAGE-1
antigen
University Hospital Zurich,
Zurich, Switzerland*
Alexander Knuth, M.D.,
Dirk Jäger, M.D.
Pilot study of immunization with proteinD MAGE-3/His and/or NY-ESO-1
protein combined with CpG 7909 in
patients with tumors expressing MAGE3 and/or NY-ESO-1 and/or LAGE-1
University of Oxford,
Oxford, United Kingdom
Vincenzo Cerundolo, M.D., Ph.D.,
MRCPath.
Pilot study of immunization with
proteinD MAGE-3/His and/or NY-ESO-1
protein combined with CpG 7909 in
patients with tumors expressing MAGE3 and/or NY-ESO-1 and/or LAGE-1
Weill Medical College of Cornell
University, New York, NY
Nasser K. Altorki, M.D.
(1) Phase II trial of immunization with
proteinD MAGE-3/His and immunological adjuvant AS02B in patients with
non-small cell lung cancer; (2) Phase II
study of NY-ESO-1 peptide plus GM-CSF
immunization in patients with non-small
cell lung cancer expressing NY-ESO-1
antigen; (3) Safety and immunological
evaluation of NY-ESO-1 plasmid DNA
(pPJV7611) cancer vaccine given by
particle mediated epidermal delivery
(PMED) in patients with NY-ESO-1 or
LAGE-1 expressing non-small cell lung
cancer; (4) A pilot study of NY-ESO-1b
peptide plus CpG 7909 and Montanide
ISA-51 in patients with advanced nonsmall cell lung cancer expressing NYESO-1 or LAGE-1
Cancer Antigen Discovery
Collaborative
Baylor College of Medicine,
Houston, TX
Rongfu Wang, Ph.D.*
34
CANCER RESEARCH INSTITUTE
Columbia University College of
Physicians & Surgeons, Ludwig
Institute Clinical Trial Center,
New York, NY
Maha Ayyoub, Ph.D.*
Danila Valmori, Ph.D.*
INSERM, Nantes, France
Francine Jotereau, Ph.D.*
Institut für Zellbiologie,
Tübingen, Germany
Cecile Gouttefangeas, Ph.D.*
Hans-Georg Rammensee, Ph.D.*
Krankenhaus Nordwest,
Frankfurt, Germany
Elke Jäger, M.D.*
Ludwig Institute for Cancer
Research, Lausanne, Switzerland
C. Victor Jongeneel, Ph.D.*
Daniel Speiser, M.D.*
Gregory Theiler*
Ludwig Institute for Cancer
Research, Melbourne, Australia
Andrew M. Scott, FRCAP, DDU*
Richard Simpson, Ph.D.*
Ludwig Institute for Cancer
Research, New York, NY
Ali O. Güre, M.D., Ph.D.*
Achim Jungbluth, M.D.*
Matthew J. Scanlan, Ph.D.*
Moscow State University,
Moscow, Russia
Dmitry Kuprash, Ph.D.*
Sergei A. Nedospasov, Ph.D., D.Sc.*
Okayama University Medical School,
Okayama, Japan
Eiichi Nakayama, M.D.*
RIKEN BioResource Center,
Tsukuba, Japan
Yuichi Obata, Ph.D.*
University Hospital Zurich,
Zurich, Switzerland
Dirk Jäger, M.D.*
Alexander Knuth, M.D.*
University of Oxford,
Oxford, United Kingdom
Vincenzo Cerundolo, M.D., Ph.D.,
MRCPath.*
University of Saarland,
Homburg, Germany
Michael Pfreundschuh, M.D.*
Christoph Renner, M.D.*
University of Virginia,
Charlottesville, VA
Michael A. Coppola, Ph.D.*
Weill Medical College of Cornell
University, New York, NY
Yao-Tseng Chen, M.D., Ph.D.*
Grants
Baylor College of Medicine,
Houston, TX
Rongfu Wang, Ph.D.
Identification of prostate cancer antigens recognized by tumor-infiltrating
lymphocytes
Dana-Farber Cancer Institute,
Boston, MA
Ellis L. Reinherz, M.D.
Thymic vaccination strategies as an
approach to prevent prostate cancer
Duke University Medical Center,
Durham, NC
Johannes Vieweg, M.D.
A safety and feasibility study of active
immunotherapy with metastatic
prostate carcinoma using autologous
dendritic cells pulsed with antigen
encoded in amplified autologous tumor
RNA
Krankenhaus Nordwest,
Frankfurt, Germany
Elke Jäger, M.D.
Phase I study of intensive course intralymphatic immunization with peptides
derived from MAGE-1, MAGE-3,
and/or NY-ESO-1 combined with GMCSF in patients with high risk stage D1
or advanced prostate cancer
Leiden University Medical Center,
Leiden, The Netherlands
Sjoerd H. van der Burg, Ph.D.
Detection and isolation of HPV-specific
T helper cells, a preclinical study
Loyola University Chicago,
Maywood, IL
Liang Qiao, M.D.
Application of MHC tetramers to the
measurement of HPV-specific CTL
responses
Ludwig Institute for Cancer
Research, Lausanne, Switzerland
Frédéric Lévy, Ph.D.*
From cancer genomics to cancer
immunotherapy
Fondazione Centro San Raffaele Del
Monte Tabor, Milan, Italy
Maria Pia Protti, M.D.*
Defining the helper epitope repertoire
on tumor antigens to study the CD4+
T cells in neoplastic patients
Massachusetts General Hospital,
Boston, MA
Martin Mihm, M.D., F.A.C.P.
Tumor infiltrating lymphocytes and
prognosis in human cutaneous
melanoma
The Hebrew University,
Jerusalem, Israel
Ofer Mandelboim, Ph.D.
Immunological markers related to
prostate cancer prognosis:
Identification of ‘lysis ligands’ for human
NK lysis receptors
Memorial Sloan-Kettering Cancer
Center, New York, NY
Jedd D. Wolchok, M.D., Ph.D.
Vaccination of AJCC stage III and IV
melanoma patients with human and
mouse tyrosinase DNA vaccines: A
phase I trial to assess safety and
immune response
Infectious Disease Research Institute,
Seattle, WA
Steven G. Reed, Ph.D.
Therapeutic vaccine studies with
prostase
Johns Hopkins University School of
Medicine, Baltimore, MD
Richard B. S. Roden, Ph.D.
Cross-genotype neutralization of human
papillomavirus and development of a
broadly protective vaccine
Kantonsspital St. Gallen,
St. Gallen, Switzerland
Marcus Groettrup, Ph.D.
Identification of prostate carcinoma
antigens by SEREX analysis and development of a PSA/PLGA anti-prostate
carcinoma vaccine
New York University School of
Medicine, New York, NY
Nina Bhardwaj, M.D., Ph.D.
Immune response to antigen bearing
dendritic cells in patients with resected
stage III melanoma
Vincent K. Tsiagbe, Ph.D.
Role of retroviral superantigens in
human lymphoma development
Ohio State University, Columbus, OH
Pan Zheng, M.D., Ph.D.
Prostate cancer tissue resource
Okayama University Medical School,
Okayama, Japan
Yuji Noguchi, M.D., Ph.D.
Expression and immunogenicity of NYESO-1 in prostate cancer
CANCER RESEARCH INSTITUTE
35
Steven J. Burakoff, M.D., is
Director of the Skirball Institute of
Biomolecular Medicine at the New
York University School of Medicine
and is the Director of the NYU
Cancer Institute, recently selected
as a participating CVC site. The
CVC trials at NYU will be testing
different vaccine formulations for
the treatment of melanoma.
“CRI’s Cancer Vaccine Collaborative is
what we’ve been missing in this field.”
-Steven J. Burakoff, M.D.
Oregon Health & Science University,
Portland, OR
Janko Nikolich-Zugich, M.D., Ph.D.
Heteroclitic CTL vaccination against
prostate cancer
University Hospital of Erlangen,
Erlangen, Germany
Gerold Schuler, M.D.
Vaccination of HLA-A1, -A2 or -A3+
stage III/IV melanoma patients with
tumor peptide-loaded autologous dendritic cells that are generated in the
absence or presence of TRANCE/
RANK-L
University of Alabama at Birmingham,
Birmingham, AL
Jiri Mestecky, Ph.D.
Humoral immunity and cytokine production in HPV-induced cervical cancer
University of California,
Los Angeles, CA
Linda Baum, M.D., Ph.D.
Apoptosis resistance and immune evasion in prostate cancer: A novel role
for galectin-1
University of Chicago, Chicago, IL
Thomas F. Gajewski, M.D.
Immunization with PSMA peptidepulsed autologous PBMC plus rhIL-12
University of Illinois at Chicago,
Chicago, IL
David J. Peace, M.D.
Phase IB pilot trial of PSA-peptide
based specific active immunotherapy in
HLA-A2+ patients with prostate cancer
University of Lausanne,
Lausanne, Switzerland
Jean-Pierre Mach, M.D.
Development of a new cancer
immunotherapy strategy using antitumor antibody fragments conjugated
to antigenic MHC/peptide complexes
University of Munich,
Munich, Germany
Gert Riethmüller, M.D.
A multicenter study in minimal residual
disease of prostate cancer: Prognostic
significance of MAGE gene expression
by disseminated tumor cells in bone
marrow
University of Pittsburgh Medical
Center, Pittsburgh, PA
John M. Kirkwood, M.D.
Immunological therapy of melanoma
Hassane M. Zarour, M.D.
Phase I/II study of vaccination with
CpG oligonucleotides (CpG 7909)
alone, or the multi-epitope vaccine containing the NY-ESO-1 and the NY-ESO
peptides alone, or the combination, in
patients with metastatic measurable
melanoma and other NY-ESO-1+ tumors
University of Queensland,
Queensland, Australia
Ian Frazer, M.D., FRCPA
Genotype specific and genotype cross
reactive cell-mediated immunity to VLPbased papillomavirus vaccines; A
phase I trial of virus-like particle
immunotherapy for HPV-associated
infection
University of Rotterdam,
Rotterdam, The Netherlands
Reinder L.H. Bolhuis, M.D.
Gerrit Stoter, M.D., Ph.D.
Immuno-gene therapy of metastatic
renal cell cancer patients
University of Virginia,
Charlottesville, VA
William P. Irvin, Jr., M.D.
Evaluation of the immunogenicity of
vaccination with synthetic peptides
mixed with GM-CSF-in-adjuvant, following surgical debulking, in patients with
advanced ovarian cancer
Craig L. Slingluff, M.D.
The human immunotherapy program at
the University of Virginia
University of Washington School of
Medicine, Seattle, WA
Alexander Fefer, M.D.
Immunological monitoring in vaccines
for HPV-associated cervical cancer
Wake Forest University,
Winston-Salem, NC
Zheng Cui, M.D., Ph.D.*
Spontaneous regression of late-stage
cancer in mice; Sequencing the candidate genes for the SR/CR mutation
responsible for innate immune
response to cancers in mice
Walter and Eliza Hall Institute of
Medical Research,
Melbourne, Australia
Andreas Strasser, Ph.D.
The role of BH3-only proteins in the
control of cell death in the prostate
36
CANCER RESEARCH INSTITUTE
Washington University School of
Medicine, St. Louis, MO
Paul M. Allen, Ph.D.
Immunologic mechanisms of host
response to prostate cancer:
Immunotherapy of prostate cancer
Peter Humphrey, M.D., Ph.D.
Immunologic mechanisms of host
response to prostate cancer:
Immunologic regulation of scatter factor/hepatocyte growth factor during
development of prostatic cancer
Robert D. Schreiber, Ph.D.
IFNγ and the development of protective
immune responses to primary tumors:
A new view of tumor immune surveillance; Immunologic mechanisms of
host response to prostate cancer:
Immunosurveillance in prostatic cancer
Kathleen Sheehan, Ph.D.
Immunologic mechanisms of host
response to prostate cancer:
Alterations in cellular sensitivity to IFNγ
during development of prostatic
tumors and metastases
Weill Medical College of Cornell
University, New York, NY
Neil H. Bander, M.D.
Phase I trial of 177Lutetium-DOTAhuJ591 in patients with hormonerefractory prostate cancer;
Prostate cancer therapy with monoclonal antibody to prostate specific
membrane antigen
Designated Grants
Beijing Cancer Hospital, Beijing, China
Yu Wang, Ph.D.*
Characterization of NY-ESO-1-specific
CD8+ T cells from different lymph
nodes and periphery blood of lung
cancers
Dana-Farber Cancer Institute,
Boston, MA
Lee Nadler, M.D.
Generation of immunity to cancer
Hadassah Medical Center,
Jerusalem, Israel
Aviram Nissan, M.D.
Identification of molecular targets for
immunotherapy in colorectal cancer
University Hospital of Erlangen,
Erlangen, Germany
Gerold Schuler, M.D.*
Sponsorship of the 7th International
Symposium on Dendritic Cells
University of Chicago, Chicago, IL
Hans Schreiber, M.D., Ph.D.
Immunological therapy and prevention
of HIV-associated cancers
Patient Support
National Prostate Cancer Coalition,
Washington, DC
Support of the “Drive Against Prostate
Cancer”
Annual Awards
Karolinska Institute,
Stockholm, Sweden
George Klein, M.D., D.Sc.*
Studies on EBV, oncogenes, tumor
suppressor genes and tumor
immunology
Willliam B. Coley Award
Ludwig Institute for Cancer
Research, Lausanne, Switzerland
Monique Zahn, Ph.D.*
Academy of Cancer Immunology’s
online journal, Cancer Immunity
Charles A. Janeway, Jr., M.D.*
(1943-2003)
Memorial Sloan-Kettering Cancer
Center, New York, NY
Malcolm A.S. Moore, D.Phil.*
Analysis of telomerase gene expression
in human cancer
Jules A. Hoffmann, Ph.D.*
CNRS Institute of Molecular and
Cellular Biology
Strasbourg, France
Bruno Lemaitre, Ph.D.*
CNRS Center for Molecular Genetics
Gif-sur-Yvette, France
Ruslan Medzhitov, Ph.D.*
Yale University School of Medicine
New Haven, CT
Oliver R. Grace Award
Hearn Jay Cho, M.D., Ph.D.*
Vaccine immunotherapy for multiple
myeloma
Nagasaki University, Nagasaki, Japan
Yasuhiro Nagata, M.D.
Induction and analysis of CD8+ CD4+ T
cells against cancer antigens in breast
and colon cancer
Strang Cancer Prevention Center,
New York, NY
Rache Simmons, M.D.*
Rhea (Rose Marie) Finnell Breast
Cancer Care Program
Anna-Maria Kellen*
Philanthropist and Cancer Research
Institute Trustee
Henry A. McKinnell, Jr., Ph.D.*
Chairman of the Board and CEO
Pfizer Inc
*Awarded in fiscal year 2003
THE CRI LEADERSHIP
“CRI has nurtured cancer immunology
from tantalizing observations into a
-Herbert F. Oettgen, M.D.
truly modern science.”
Herbert F. Oettgen, M.D.,
has served on the CRI Scientific
Advisory Council since 1971,
playing a significant role in
expanding its scope. He is
currently an Associate Director
of the Council and a Member of
the Immunology Program at
Memorial Sloan-Kettering
Cancer Center.
SAC meeting, early 1970s; left to right:
Lloyd Old, Helen Nauts, Edmund Klein, Robert Good, Herbert Oettgen, and Edward Boyse.
38
THE SCIENTIFIC ADVISORY COUNCIL
The Scientific Advisory Council is composed of distinguished scientists from 13 countries
who guide the development of cancer immunology without politics or bottom-line pressure.
They include 4 Nobel Prize winners, 24 members of the National Academy of Sciences,
and 23 members of the Academy of Cancer Immunology.
The Council’s universally respected judgment is put into effective action through the power
of the purse; all CRI funding decisions, from predoctoral training awards to grants for clinical trials, are arrived at in deliberation by Council members.
Director
Lloyd J. Old, M.D.2,3,5,6
Ludwig Institute for Cancer
Research
New York, New York
Associate Directors
Glenn Dranoff, M.D.3
Dana-Farber Cancer Institute
Boston, Massachusetts
Carl F. Nathan, M.D.3,4
Weill Medical College of
Cornell University
New York, New York
Herbert F. Oettgen, M.D.3
Memorial Sloan-Kettering
Cancer Center
New York, New York
Benvenuto G. Pernis, M.D.4
Columbia University
College of Physicians &
Surgeons
New York, New York
Ellen Puré, Ph.D.4,6
The Wistar Institute
Philadelphia, Pennsylvania;
and Ludwig Institute for
Cancer Research
New York, New York
Robert D. Schreiber,
Ph.D.3,4,5,6
Washington University School
of Medicine
St. Louis, Missouri
Richard Axel, M.D.2
Columbia University
College of Physicians &
Surgeons
New York, New York
Baruj Benacerraf, M.D.1,2
Dana-Farber Cancer Institute
Boston, Massachusetts
Sir Walter F. Bodmer,
Ph.D., F.R.S.2
Hertford College
Oxford, England
Thierry Boon, Ph.D.3
Ludwig Institute for Cancer
Research
Brussels, Belgium
Edward A. Boyse, M.D.2
University of Arizona
Tucson, Arizona
Harvey Cantor, M.D.2
Dana-Farber Cancer Institute
Boston, Massachusetts
Jean-Charles Cerottini, M.D.3
Ludwig Institute for Cancer
Research
Lausanne, Switzerland
Peter Cresswell, Ph.D.2,4
Yale University School of
Medicine
New Haven, Connecticut
Jean Dausset, M.D.1,2
Fondation Jean Dausset CEPH
Paris, France
Members
Garry I. Abelev, Ph.D.3
Russian Cancer Research
Center
Moscow, Russia
Emil Frei III, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts
Gideon Goldstein, M.D., Ph.D.
Thymon, LLC
Short Hills, New Jersey
Philip D. Greenberg, M.D.3,4
University of Washington
School of Medicine and
Fred Hutchinson Cancer
Research Center
Seattle, Washington
Jordan U. Gutterman, M.D.
The University of Texas M.D.
Anderson Cancer Center
Houston, Texas
Sen-itiroh Hakomori, M.D.,
Ph.D.2
University of Washington
School of Medicine
Seattle, Washington
Karl Erik Hellström, M.D.
Pacific Northwest Research
Foundation
Seattle, Washington
Richard J. Hodes, M.D.
National Institute on Aging
Bethesda, Maryland
Alan N. Houghton, M.D.3
Memorial Sloan-Kettering
Cancer Center
New York, New York
John M. Kirkwood, M.D.
Pittsburgh Cancer Institute
University of Pittsburgh
Medical Center
Pittsburgh, Pennsylvania
George Klein, M.D., D.Sc.2,3
Karolinska Institute
Stockholm, Sweden
Alexander Knuth, M.D.3,6
University Hospital Zurich
Zurich, Switzerland
John Kuriyan, Ph.D.2
University of California,
Berkeley, California
Richard A. Lerner, M.D.2
The Scripps Research
Institute
La Jolla, California
Dan R. Littman, M.D., Ph.D.
New York University School of
Medicine
New York, New York
Tak W. Mak, Ph.D., D.Sc.,
M.D., F.R.S.2,4
Advanced Medical Discovery
Institute, University Health
Network
Toronto, Canada
Philippa C. Marrack, Ph.D.2
National Jewish Medical and
Research Center and
University of Colorado Health
Sciences Center, HHMI
Denver, Colorado
Hugh O. McDevitt, M.D.2
Stanford University School of
Medicine
Stanford, California
Ira Mellman, Ph.D.5
Yale University School of
Medicine
New Haven, Connecticut
Malcolm A.S. Moore, D.Phil.
Memorial Sloan-Kettering
Cancer Center
New York, New York
Donald L. Morton, M.D.
John Wayne Cancer Institute
Santa Monica, California
Lee Nadler, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts
Stanley G. Nathenson,
M.D.2,4
Albert Einstein College of
Medicine
Bronx, New York
CANCER RESEARCH INSTITUTE
Sir Gustav Nossal, M.D.,
Ph.D., F.R.S.2
The University of Melbourne
Melbourne, Australia
Victor Nussenzweig, M.D.,
Ph.D.
New York University School of
Medicine
New York, New York
Drew M. Pardoll, M.D.,
Ph.D.3,4
The Johns Hopkins University
School of Medicine
Baltimore, Maryland
William E. Paul, M.D.2
National Institutes of Health
Bethesda, Maryland
Klaus Rajewsky, M.D.2,3
Harvard Medical School,
The CBR Institute for
Biomedical Research
Boston, Massachusetts
Anjana Rao, Ph.D.4
Harvard Medical School,
The CBR Institute for
Biomedical Research
Boston, Massachusetts
Jeffrey V. Ravetch, M.D.,
Ph.D.
The Rockefeller University
New York, New York
Gert Riethmüller, M.D.3
University of Munich
Munich, Germany
Bijan Safai, M.D., D.Sc.
New York Medical College
Valhalla, New York
Lawrence E. Samelson, M.D.4
National Cancer Institute
Bethesda, Maryland
Stuart F. Schlossman, M.D.2,3
Dana-Farber Cancer Institute
Boston, Massachusetts
Thomas A. Waldmann, M.D.2,3
National Cancer Institute
Bethesda, Maryland
Hans Schreiber, M.D., Ph.D.3,4
University of Chicago
Chicago, Illinois
David W. Weiss, Ph.D.,
D.Phil.
The Hebrew UniversityHadassah Medical School
Jerusalem, Israel
Gregory W. Siskind, M.D.
Weill Medical College of
Cornell University
New York, New York
Pramod K. Srivastava, Ph.D.3
University of Connecticut
School of Medicine
Farmington, Connecticut
Ursula B. Storb, M.D.4
University of Chicago
Chicago, Illinois
Zongtang Sun, M.D.
Cancer Institute
Chinese Academy of
Medical Sciences
Beijing, People's Republic
of China
Tomio Tada, M.D., D.M.S.
Science University of Tokyo
Research Institute for
Biological Sciences
Tokyo, Japan
Toshitada Takahashi, M.D.3
Aichi Cancer Center Research
Institute
Nagoya, Japan
Susumu Tonegawa, Ph.D.1,2
Massachusetts Institute of
Technology
Cambridge, Massachusetts
Giorgio Trinchieri, M.D.3,4,5
Schering-Plough Laboratory of
Immunological Research
Dardilly, France
Rolf M. Zinkernagel, M.D.,
Ph.D.1,2,3
University of Zurich
Zurich, Switzerland
Honorary Members
Robert W. Baldwin, Ph.D.,
F.R.C. Path.
University of Nottingham
Nottingham, England
Joseph H. Burchenal, M.D.
(Retired)
Memorial Sloan-Kettering
Cancer Center
New York, New York
39
Zoltan Ovary, M.D.
New York University
School of Medicine
New York, New York
Richmond T. Prehn, M.D.3
(Retired)
University of Washington
Seattle, Washington
Bernard Roizman, Sc.D.2
University of Chicago
Chicago, Illinois
Otto Westphal, D.Sc., M.D.
(Retired)
Max Planck Institute for
Immunobiology
Freiburg, Germany
Sir Michael Woodruff, M.D.,
F.R.S.
(Retired)
University of Edinburgh
School of Medicine
Edinburgh, Scotland
Legend
Isaac Djerassi, M.D.
Mercy Catholic Medical Center
Philadelphia, Pennsylvania
1
2
James F. Holland, M.D.
Mount Sinai School of Medicine
New York, New York
3
Henri Isliker, M.D.
University of Lausanne
School of Medicine
Lausanne, Switzerland
5
George B. Mackaness, M.D.,
D.Phil., F.R.S.
(Retired)
Squibb Institute for Medical
Research
Princeton, New Jersey
Georges Mathé, M.D.
Institute of Oncology and
Immunogenetics
Villejuif, France
4
6
Nobel Laureate
Member, National Academy
of Sciences
Member, Academy of
Cancer Immunology
Member, Fellowship Review
Committee
Member, Investigator Award
and Predoctoral Program
Review Committee
Member, Grant Review
Committee
40 BOARD OF TRUSTEES AND JUNIOR COUNCIL
A passion for the cause and a grasp of practical realities are key traits shared by
CRI’s Board of Trustees. Members apply skills honed in finance, communications, and other
fields to ensure our sound fiscal operation and the success of fundraising and
public-relations events.
Their efforts are reinforced by the CRI Junior Council, made up of successful younger
professionals dedicated to achieving annual fundraising goals.
Board of Trustees
Chairman of the Board
Treasurer
Ann W. Jackson
Group President
Time Inc. Women’s Group
New York, New York
Bruce D. Dixon
Retired Partner
Ernst & Young
Greenwich, Connecticut
Vice Chairmen of the Board
Secretary
Carter F. Bales
Co-Managing Partner
The Wicks Group of
Companies, L.L.C.
New York, New York
Thomas G. Mendell
Partner
The Beacon Group, LP
New York, New York
Oliver R. Grace, Jr.
President & CEO
Anderson Group, Inc.
Glen Head, New York
Daniel L. Gray
Chairman & CEO
Northstar Companies, Inc.
Lutherville, Maryland
Thomas S. Johnson
Chairman & CEO
GreenPoint Financial Corp.
New York, New York
Trustees
Edgar R. Berner
Senior Advisor
The Wicks Group of
Companies, L.L.C.;
Partner
John Lang, Inc.
New York, New York
Carlos A. Ferrer
Partner
Ferrer Freeman & Company,
LLC
Greenwich, Connecticut
Donald J. Gogel
President & CEO
Clayton, Dubilier & Rice, Inc.
New York, New York
Jacques C. Nordeman
Chairman
Nordeman Grimm, Inc.
New York, New York
Julian H. Robertson, Jr.
Chairman
Tiger Management LLC
New York, New York
President
Patrick J. McGrath
Pelham, New York
Geoffrey O. Coley
Managing Director
Citigroup
New York, New York
Maurice J. Cunniffe
Chairman & CEO
AO Capital Corp.
Greenwich, Connecticut
Stuart P. Davidson
Managing Director
Labrador Ventures
Palo Alto, California
Richard M. DeMartini
President, Asset
Management Group
Bank of America
New York, New York
Glenn J. DeSimone
President & CEO
Publicis Healthcare
Communications Group
International
New York, New York
William O. Grabe
Partner
General Atlantic Partners
Greenwich, Connecticut
Mrs. Stephen M. Kellen
New York, New York
Alexander P. Lynch
Chairman, North American
Mergers & Acquisitions Group
J.P. Morgan Securities, Inc.
New York, New York
Lief D. Rosenblatt
Senior Managing Member
Satellite Asset
Management, L.P.
New York, New York
Frank V. Sica
Managing Partner
Soros Private Funds
Management LLC
New York, New York
Heidi Ueberroth
Executive Vice President
NBA Entertainment
New York, NY
Vance Van Dine
Advisory Director
Morgan Stanley Dean
Witter & Co.
New York, New York
Honorary Trustees
William E. Murray, Esq.
Chairman
Samuel Freeman Charitable
Trust
New York, New York
Lloyd J. Old, M.D.
Director
Ludwig Institute for Cancer
Research
New York, New York
Andrew M. Paul
Chairman
Enhanced Capital
Partners LLC
New York, New York
Robert A. Posner
Managing Director
Commonwealth Holding, L.P.
Brookline, Massachusetts
Marjorie Atwood, Ph.D.
Irvington, Virginia
Howard P. Berkowitz
Managing Partner
BlackRock HPB Management
New York, New York
Roy J. Bostock
Chairman and CEO
B/com3, Inc.
New York, New York
The Honorable Bill Bradley
Managing Director
Allen & Company, Inc.
New York, New York
Donald G. Calder
President
G.L. Ohrstrom & Co., Inc.
New York, New York
Mrs. Richard B. Englund
New York, New York
CANCER RESEARCH INSTITUTE
Wilbur H. Friedman, Esq.
Partner
Proskauer Rose LLP
New York, New York
Wayne T. Jervis, Jr.
Los Angeles, California
Mrs. Charles G. Gambrell
Charlotte, North Carolina
David B. Kinney
Managing Partner
Kinco
Great Falls, Virginia
Charles M. Grace
Los Angeles, California
David H. Shepard
Coronado, California
Mrs. Oliver R. Grace
New York, New York
Winthrop H. Smith, Jr.
Chairman
WHS Holding LLC
Greenwich, Connecticut
Junior Council
Co-Chairs
Leslie DeBauge
New York, New York
Lara S. Trafelet
New York, New York
Members
Founder
Skardon Baker
Vice President
JPMorgan Mergers &
Acquisitions
New York, New York
Alan J. Hirschfield
Wilson, Wyoming
Helen Coley Nauts, D.Sc., Hon.
1907-2001
Julia Parker Benello
San Francisco, California
Arthur L. Jacobson
Vice President - Investments
SmithBarney
Palm Desert, California
Founding Chairman
Kyle Clark
Vice President, Human
Resources Manager
BBDO
New York, New York
Joyce Green
Westhampton Beach,
New York
Oliver R. Grace
1909-1992
41
“When your family is hit by cancer, you
realize how urgent this work is.” -Leslie DeBauge
Leslie DeBauge is founder and
Co-Chairman of CRI’s Junior
Council, many of whose members
have had their lives touched by
cancer; “a proactive approach is
critical for the long term,” she
believes. She is a consultant on
strategic planning and margin
improvement for media and
communications companies.
John B. Fitzgibbons
New York, New York
Gregory R. Myers
New York, New York
Eric Rosen
New York, New York
Robin K. Stein
Associate Broker
Sotheby’s International Realty
New York, New York
Remy W. Trafelet
Managing Partner
Trafelet and Company
New York, New York
42 FINANCIAL STATEMENTS
Financial Statements for the
Years ended June 30, 2003 and 2002
With Report of Independent Auditors
To the Board of Trustees of Cancer Research Institute, Inc.
We have audited the accompanying statements of financial position of Cancer Research
Institute, Inc. (the “Institute”) as of June 30, 2003 and 2002, and the related statements of activities and cash flows for the years then ended. These financial statements
are the responsibility of the Institute’s management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally accepted in
the United States. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the
amounts and disclosures in the financial statements. An audit also includes assessing
the accounting principles used and significant estimates made by management, as well
as evaluating the overall financial statement presentation. We believe that our audits
provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material
respects, the financial position of the Institute at June 30, 2003 and 2002, and the
changes in its net assets and its cash flows for the years then ended in conformity with
accounting principles generally accepted in the United States.
August 28, 2003
CANCER RESEARCH INSTITUTE
43
Statements of Financial Position
June 30
Assets
Cash and cash equivalents
Pledges receivable—net (Note 2)
Other receivables
Prepaid expenses
Long-term investments, at fair value (Note 3)
Office equipment and leasehold improvements—net of accumulated depreciation and amortization
($518,163 in 2003 and $481,285 in 2002)
Total assets
Liabilities and net assets
Accounts payable and accrued expenses
Grants and fellowships payable (Note 5)
Deferred rent (Note 4)
Total liabilities
2003
$
$
$
Net assets:
Unrestricted:
Board designated (Note 8)
Other
Total unrestricted
Temporarily restricted (Note 7)
Total net assets
Total liabilities and net assets
See accompanying notes.
10,616,649 $
19,636,058
206,624
89,131
10,636,015
8,480,736
25,407,150
20,335
26,788
8,718,504
65,374
41,249,851 $
94,848
42,748,361
180,638 $
22,931,867
–
23,112,505
61,617
22,728,224
4,396
22,794,237
1,424,899
1,021,148
2,446,047
$
2002
15,691,299
18,137,346
41,249,851 $
1,236,432
351,275
1,587,707
18,366,417
19,954,124
42,748,361
44
CANCER RESEARCH INSTITUTE
Statements of Activities
Year ended June 30
Unrestricted
Revenues, gains, reclassifications
and other support
Contributions:
General, trustee, and related
Combined federal campaigns
Bequests/memorials
Return on investments (Note 3)
Special events:
Income
Direct costs
Special events—net
$ 3,813,375 $
180,024
2,554,015
345,502
1,318,246
(289,485)
1,028,761
Designated contributions
2,000,848
Miscellaneous
57,996
Net assets released from restrictions
(Note 7)
4,073,116
Total revenues, gains, reclassifications
and other support
14,053,637
2003
Temporarily
Restricted
Total
– $ 3,813,375
776,248
956,272
–
2,554,015
–
345,502
–
–
–
Unrestricted
$ 2,632,188 $
401,726
2,136,820
(555,808)
1,318,246
(289,485)
1,028,761
1,264,749
(303,166)
961,583
2,622,598
57,996
3,660,923
67,105
(4,073,116)
–
3,481,883
(2,675,118)
11,378,519
12,786,420
621,750
–
2002
Temporarily
Restricted
Total
– $ 2,632,188
787,616
1,189,342
10,000
2,146,820
–
(555,808)
–
–
–
15,800,000
–
(3,481,883)
13,115,733
1,264,749
(303,166)
961,583
19,460,923
67,105
–
25,902,153
Expenses (Note 9)
Program:
Science, medical and research information
and communications
1,352,174
Research
10,470,822
Total program
11,822,996
–
–
–
1,352,174
10,470,822
11,822,996
1,439,883
11,193,074
12,632,957
–
–
–
1,439,883
11,193,074
12,632,957
Administration
Marketing and development
Total expenses
–
–
–
623,491
748,810
13,195,297
593,768
868,329
14,095,054
–
–
–
593,768
868,329
14,095,054
Change in net assets
Net assets, beginning of year
Net assets, end of year
See accompanying notes.
623,491
748,810
13,195,297
858,340
(2,675,118)
(1,816,778)
(1,308,634) 13,115,733
11,807,099
1,587,707
18,366,417
19,954,124
2,896,341
5,250,684
8,147,025
$ 2,446,047 $15,691,299 $18,137,346 $ 1,587,707 $18,366,417 $19,954,124
CANCER RESEARCH INSTITUTE
45
Statements of Cash flows
Year ended June 30
Cash flows from operating activities
Change in net assets
Adjustments to reconcile change in net assets to net
cash provided by (used in) operating activities:
Depreciation and amortization
Contributed investment securities
Net realized and unrealized losses on investments
Changes in operating assets and liabilities:
Net decrease (increase) in pledges receivable,
other receivables, and prepaid expenses
Net increase (decrease) in accounts payable and
accrued expenses, grants and fellowships
payable, and deferred rent
Net cash provided by (used in) operating activities
Cash flows from investing activities
Purchases of office equipment and leasehold improvements
Net purchases of long-term investments
Net cash used in investing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
2003
2002
$ (1,816,778) $11,807,099
36,878
(624,213)
138,745
25,779
–
887,167
5,522,460
(12,517,819)
318,268
3,575,360
(305,942)
(103,716)
(7,404)
(1,432,043)
(1,439,447)
(73,194)
(233,396)
(306,590)
2,135,913
(410,306)
8,480,736
8,891,042
$10,616,649 $ 8,480,736
See accompanying notes.
Notes to Financial Statements
1. Organization and Summary of Significant
Accounting Policies
Organization - The Cancer Research Institute, Inc. (the “Institute”)
was founded in 1953 to foster the field of cancer immunology in
the belief that the body’s immune system can be used to control
and cure cancer. The Institute supports research with the immediate aim of increasing our understanding of the immune system
and with the ultimate goal of developing immunological methods
for the prevention and treatment of human cancer. The Institute
also functions as a definitive source of public information on cancer immunology and cancer treatment.
The Institute is a nonprofit corporation exempt from income tax
under Section 501(c)(3) of the Internal Revenue Code. All contributions are considered to be available for unrestricted use
unless specifically restricted by the donor.
Net Assets - Temporarily restricted net assets are amounts that
have been restricted in use by donor specification. The Institute
has established a policy whereby donor-restricted contributions
whose restrictions are met in the same reporting period are
reported as unrestricted support.
Cash Equivalents - Cash equivalents consist of money market
funds with a maturity at the time they are acquired of no more
than three months, except those held as part of the investment
portfolio.
Investments - Investments are measured at fair value in the
accompanying statements of financial position. The following
methods and assumptions were used by the Institute in estimating the fair value of its financial instruments:
Cash and cash equivalents: The carrying amounts reported in
the accompanying statements of financial position for cash and
cash equivalents approximate fair value.
Equities and debt securities: Fair values of equities and all debt
securities are based on quoted market prices.
Bequests - The Institute is a beneficiary under various wills and
trust agreements, the total realizable amounts of which are not
presently determinable. The Institute’s interest in bequests and
trusts is recorded as revenue when it receives notice such interest has become unconditional.
Office Equipment and Leasehold Improvements - Office equipment is depreciated over its estimated useful life using the
straight-line method. Leasehold improvements are amortized
over the term of the lease.
Fellowships, Investigatorships and Grants - The Institute awards
fellowships, investigatorships and grants covering periods of one
to four years for the purpose of medical research. These awards
are recorded as expenses at the time they become unconditional, which is usually when they are awarded.
46
CANCER RESEARCH INSTITUTE
Science, Medical and Research Information and Communications Science, medical and research information and communications
include costs primarily related to providing the public with information concerning cancer immunology, responding to inquiries from
the public concerning cancer and communicating with applicants
and awardees.
Contributed Services - The Institute receives considerable contributed services. The fair value of contributed services provided
by the Institute’s Scientific Advisory Council approximated
$270,000 and $255,000 for the years ended June 30, 2003
and 2002, respectively, and has been recorded in the accompanying financial statements. Other contributed services have not
been recognized as revenues and are not reported in the accompanying financial statements because they do not meet the criteria for recognition specified in Statement of Financial Accounting
Standards No. 116, Accounting for Contributions Received and
Contributions Made.
Use of Estimates - The preparation of financial statements in
conformity with accounting principles generally accepted in the
United States requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results could differ from those estimates.
The return on investments for the years ended June 30, 2003
and 2002 was as follows:
Interest and dividends
$
Net realized and unrealized losses
$
2003
484,247 $
(138,745)
345,502 $
2002
331,359
(887,167)
(555,808)
4. Commitments
The Institute is obligated under a ten-year noncancelable lease for
office space, expiring April 30, 2013, as follows:
2004
2005
2006
2007
2008
Thereafter
Total
$
150,000
150,000
150,000
150,000
154,167
845,833
$ 1,600,000
Rent expense approximated $150,000 and $142,000 for the
years ended June 30, 2003 and 2002, respectively.
5. Grants and Fellowships Payable
2. Pledges Receivable
The Institute has pledges receivable as of June 30 as follows:
As of June 30, 2003 and 2002, the Institute has unconditional
grants and fellowships payable as follows:
Due within one year
Due between two and five years
Total
2003
2002
$ 7,515,001 $ 7,666,168
13,567,440
19,754,829
21,082,441
27,420,997
2003
Due within one year
$12,716,205
Due between two and five years
10,752,166
Total
23,468,371
Present value discount
at a rate of 5%
Pledges receivable—net
(1,446,383)
(2,013,847)
$19,636,058 $25,407,150
Present value discount at rates of 3%-5%
and 5%, respectively
(536,504)
(823,822)
Grants and fellowships payable
$22,931,867 $22,728,224
Approximately 94% and 95% of the Institute’s fiscal 2003 and
2002 pledges receivable, respectively, are due from a single
donor.
3. Investments
Investments, which management intends to hold for more than
one year, are classified as long-term. The market values of longterm investments at June 30, 2003 and 2002 were as follows:
Equity securities
Fixed income
Mutual funds
Bonds
U.S. Government obligations
Mortgage-backed securities
Cash equivalents and other
Total long-term investments
2003
2002
$ 6,407,492 $ 4,384,150
3,765,015
–
130,564
1,104,636
–
921,835
106,763
726,436
–
978,129
226,181
603,318
$10,636,015 $ 8,718,504
2002
$11,253,128
12,298,918
23,552,046
6. Allocation of Joint Costs of Informational Materials
In accordance with the AICPA’s Statement of Position 98-2,
Accounting for Costs of Activities of Not-for-Profit Organizations
and State and Local Government Entities that Include Fund Raising
(“SOP 98-2”), the Institute incurred joint costs in the placement of
advertisements aggregating $275,163 and $260,234 in fiscal
2003 and 2002, respectively. The Institute allocated such costs
in accordance with SOP 98-2 as follows:
June 30
Marketing and development
$
Science, medical and research
information and communication
2003
111,453
Administration
Total
993
275,163
$
$
162,717
2002
104,158
156,076
$
–
260,234
CANCER RESEARCH INSTITUTE
47
7. Temporarily Restricted Net Assets
Temporarily restricted net assets as of June 30, 2003 and 2002 include the following amounts that are restricted for the following programs or activities by donor specifications:
2003
2002
Clinical and laboratory research
$14,915,051 $17,578,801
Combined federal campaign restricted for future periods
776,248
787,616
$15,691,299 $18,366,417
Temporarily restricted net assets were released from restrictions in fiscal 2003 and 2002 in fulfillment of the following purposes:
2003
2002
$ 3,285,500 $ 2,552,573
787,616
929,310
$ 4,073,116 $ 3,481,883
Clinical and laboratory research
Combined federal campaign restricted for future periods
8. Unrestricted Board Designated Net Assets
Balances, June 30, 2001
$
Contributions
Interest income
Net realized and unrealized gains
Clinical and laboratory research grants and fellowships
Balances, June 30, 2002
Contributions
Interest income
Net realized and unrealized gains
Clinical and laboratory research grants and fellowships
Balances, June 30, 2003
$
Elaine R.
Shepard
Memorial
Fund
231,578 $
–
15,952
267
–
247,797
–
15,545
34,254
–
297,596 $
John Hans
Old and
Roger E.
Edna Alice
Green
Old
Memorial
Memorial
Fund
Fund
690,414 $
45,509 $
–
–
46,261
3,190
775
53
–
–
737,450
48,752
–
–
46,635
3,109
102,762
6,851
–
(46,584)
886,847 $
12,128 $
Gar
Reichman
Fund of
Cancer
Total
Research
Board
Institute
Designated
218,059 $ 1,185,560
69,775
69,775
14,357
79,760
242
1,337
(100,000)
(100,000)
202,433
1,236,432
86,056
86,056
12,436
77,725
27,403
171,270
(100,000)
(146,584)
228,328 $ 1,424,899
48
CANCER RESEARCH INSTITUTE
9. Functional Expenses
Science, Medical
and Research
Marketing
Information and
Year ended June 30, 2002
Research
and
Communications
Fellowship program
$ 4,022,845 $
–
Investigator Award program
1,000,000
–
Predoctoral program
675,000
–
Preclinical grants program
2,070,000
–
Designated grants program
499,544
–
Clinical trials program
2,203,433
–
Salaries, benefits and related taxes
–
568,806
Professional fees
–
323,733
Printing, postage and supplies
–
64,349
Rent
–
47,123
Telephone
–
4,736
Advertising
–
162,717
Depreciation and amortization
–
12,906
Miscellaneous
–
167,804
2003 subtotals
10,470,822
1,352,174
Less special events
–
–
2003 totals
$ 10,470,822 $ 1,352,174
Administration
$
$
Special
Development
– $
–
–
–
–
–
366,002
73,557
68,282
47,447
4,471
993
12,906
49,833
623,491
–
623,491 $
–
–
–
–
–
–
477,687
4,455
63,790
55,280
4,587
111,453
11,066
20,492
748,810
–
748,810
Events
$
$
Total
– $ 4,022,845
–
1,000,000
–
675,000
–
2,070,000
–
499,544
–
2,203,433
–
1,412,495
64,202
465,947
37,488
233,909
–
149,850
–
13,794
–
275,163
–
36,878
187,795
425,924
289,485
13,484,782
(289,485)
(289,485)
– $ 13,195,297
Science, Medical
and Research
Marketing
Information and
Year ended June 30, 2002
Research
and
Communications
Fellowship program
$ 3,147,382 $
–
Investigator Award program
1,200,000
–
Predoctoral program
1,800,000
–
Preclinical grants program
1,450,000
–
Designated grants program
476,715
–
Clinical trials program
3,118,977
–
Salaries, benefits and related taxes
–
555,900
Professional fees
–
280,421
Printing, postage and supplies
–
69,907
Rent
–
44,413
Telephone
–
5,880
Advertising
–
164,716
Depreciation and amortization
–
9,022
Miscellaneous
–
309,624
2002 subtotals
11,193,074
1,439,883
Less special events
–
–
2002 totals
$ 11,193,074 $ 1,439,883
Administration
$
$
–
–
–
–
–
–
358,769
59,936
74,395
44,755
5,369
–
9,022
41,522
593,768
–
593,768
Special
Development
$
$
–
–
–
–
–
–
519,265
46,682
52,816
53,046
5,369
140,139
7,735
43,277
868,329
–
868,329
Events
$
$
Total
– $ 3,147,382
–
1,200,000
–
1,800,000
–
1,450,000
–
476,715
–
3,118,977
–
1,433,934
61,511
448,550
40,088
237,206
–
142,214
–
16,618
–
304,855
–
25,779
201,567
595,990
303,166
14,398,220
(303,166)
(303,166)
– $ 14,095,054
10. Employee Benefit Plan
Effective July 1, 1989, the Institute established a defined contribution retirement plan which provides for the Institute to make monthly
contributions of at least 5% of the compensation of eligible employees. Eligible employees are those who have one year of service with the
Institute. In addition, the Institute may contribute to the plan a discretionary amount equal to a percentage of compensation which is to
be determined each plan year by the Institute. The plan allows the participants to make voluntary contributions up to limited amounts.
During fiscal 2003 and 2002, the Institute contributed $92,395 and $80,674, respectively, to the plan. Discretionary contributions
made by the Institute vest over a period of three years.
© 2003 Cancer Research Institute
Editor
Lynne A. Harmer
Writer
Bill McCullam
Designer
Ian Plimsoll
Printer
Hu-tech Graphics, NYC
PAST IS PROLOGUE
Cancer Research Institute
681 Fifth Avenue, New York, NY 10022-4209
www.cancerresearch.org